



SURVEY ON THE GRANT AND PUBLICATION OF “SUPPLEMENTARY PROTECTION CERTIFICATES” FOR MEDICINAL AND PHYTOPHARMACEUTICAL PRODUCTS OR EQUIVALENT INDUSTRIAL PROPERTY RIGHTS (SPCs)

adopted by the PCIPI Executive Coordination Committee at its fourteenth session on May 20, 1994, and further updated by the International Bureau in January 2002

INTRODUCTION

1. This Survey reflects information provided by 56 industrial property offices and organizations on the grant and publication of SPCs.
2. A summary of the data contained in the Survey and examples of announcements regarding applications for SPCs and the grant thereof are given on pages following the replies to the last Question 12 and in the Appendices to the Survey.
3. For a definition of an SPC, please refer to the “Glossary of Terms Concerning Industrial Property Information and Documentation,” published in Volume IV, Part 10, of the WIPO Handbook on Industrial Property Information and Documentation CD-ROM.
4. The questionnaire submitted to industrial property offices for the preparation of this Survey contained the following questions:

QUESTION 1: Does your Office grant “supplementary protection certificates” or equivalent industrial property rights (SPCs) that extend the validity of patents covering medicinal, pharmaceutical, agrochemical or cognate products and phytopharmaceutical products?.....2

QUESTION 2: Will your Office start granting SPCs in the future?.....2

QUESTION 3: Please specify the legal basis for granting SPCs (national law, regional regulation, etc.).....3

QUESTION 4: Please give the name of the SPC granted by your Office.....5

QUESTION 5: Please specify for which fields of technology or which products an SPC can be obtained (for example, medicinal products, pharmaceutical products, phytopharmaceutical products, herbicides, agro-chemicals, all products subject to regulatory approval for marketing, etc.).....7

QUESTION 6: Does your Office publish or intend to publish the receipt of an application for an SPC? (If “Yes,” please attach specimen of a front page of an SPC and/or of announcements regarding SPCs made in an Official Gazette.).....8

QUESTION 7: If your reply to question 6 is “Yes,” please state the minimum elements that a publication must contain.....9

QUESTION 8: Does your Office publish or intend to publish the fact that an SPC has been granted? (If “Yes,” please attach specimen of a front page of an SPC and/or of announcement regarding the grant of SPCs made in an Official Gazette.).....13

QUESTION 9: If your reply to question 8 is “Yes,” please state the minimum elements that a publication must contain.....14

QUESTION 10: In what form does your Office make or intend to make the publications referred to in questions 6 and 8?.....18

QUESTION 11: If your Office enters or intends to enter data from the documents relating to SPCs in online databases (internal or commercial), please give the name(s) of the database(s) and specify the bibliographic data elements:.....22

QUESTION 12: If your Office assigns or intends to assign specific application and/or registration numbers to SPCs, please give details.....25



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.2

QUESTION 1:

Does your Office grant "supplementary protection certificates" or equivalent industrial property rights (SPCs) that extend the validity of patents covering medicinal, pharmaceutical, agrochemical or cognate products, and phytopharmaceutical products?

(a) In the field of medicinal products

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, SE, US (24)

No: AP, BG, BY, CL, CN, CU, EA, EP, HU, JO, KZ, LT, MA, MC, MK, MX, MY, NZ, OA, OM, PA, PL, PT, QA, RO, RU, SI, SK, TM, TR, UA, VE (32)

Remarks:

MX : At the present time, there is no provision for the grant of SPCs in the Industrial Property Law, which has been in force since October 1, 1994. With regard to patents granted under the Law on the Development and Protection of Industrial Property, which was in force until September 1994, there is a provision for the grant of a three-year extension, provided that an exploitation license has been granted to a legal entity in majority Mexican ownership (Article 23 of the Law on the Development and Protection of Industrial Property).

UA : Although there is no SPC protection as such, an amendment to the Law of Ukraine on the Protection of Inventions and Utility Models provides for the extension of the term of patent protection for medicinal, animal or plant protection (phytopharmaceutical) products, the use of which is subject to an authorization issued by the competent authority. At the request of the patentee, the term of protection may be extended for the period that has elapsed from the filing of the application until the date of the authorization, up to a maximum of five years (Art. 6. of the amended Law referred to).

SI : The current legislation provides for an extension of not more than five years immediately on expiry of patents for which protection was sought on or after January 1, 1993.

(b) In the field of phytopharmaceutical products

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, SE, US (24)

No: AP, BG, BY, CL, CN, CU, EA, EP, HU, JO, KZ, LT, MA, MC, MK, MX, MY, NZ, OA, OM, PA, PL, PT, QA, RO, RU, SI, SK, TM, TR, UA, VE (32)

Remarks:

KR : Phytopharmaceutical products are protected and treated in the same way as medicinal products.

SI : See explanation given in connection with question 1(a).

UA : See explanation given in connection with question 1(a).

QUESTION 2:

Will your Office start granting SPCs in the future?

(a) In the field of medicinal products

Yes: BG, HU, KZ, LT, SI, SK (6)

No: AP, BY, CA, CN, CU, EP, MC, MK, MX, MY, NZ, OM, PA, PL, QA, RO, VE (17)

(b) In the field of phytopharmaceutical products

Yes: BG, HU, KZ, LT, SI, SK, (6)

No: AP, CL, CN, CU, MC, MK, MX, MY, NZ, OM, PA, PL, QA, RO, VE (15)



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.3

Remarks:

- EP : With regard to the EPO, it should be noted that the grant and publication of SPCs for medicinal and for phytopharmaceutical products would be a matter for Contracting States under the European Patent Convention.
- HU : Hungary will start granting SPCs in the field of medicinal and phytopharmaceutical products as from the date of accession to the European Union.
- RO : New draft legislation is prepared for being considered by the Romanian Parliament in the future.
- SI : New draft legislation is under consideration by the Slovenian Parliament.
- SK : New draft legislation is under consideration by the Parliament of the Slovak Republic.

QUESTION 3:

Please specify the legal basis for granting SPCs (national law, regional regulation, etc.).

(a) In the field of medicinal products

- AT : Council Regulation (EEC) No. 1768/92 of June 18, 1992, and national legislation: Federal Law on Supplementary Protection Certificates 1996, No. 11/1997.
- AU : Australian Patents Act of 1990 (Sections 70 to 79 and Schedule 1); Australian Patents Regulations of 1991 (Regulation 6.7-6-11).
- BE : Royal Decree of January 5, 1993, concerning applications and grants of supplementary protection certificates for medicinal products (in French: "Arrêté royal du 05 janvier 1993, relatif à la demande et à la délivrance des certificats complémentaires de protection pour les médicaments) and Council Regulation (EEC) No. 1768/92 of June 18, 1992 (concerning the creation of a supplementary protection certificate for medicinal products).
- CH : Federal Law on Patents for Invention of June 25, 1954 (amended on February 3, 1995). Ordinance on Patents for Invention of October 19, 1977 (amended on May 17, 1995). The amendments concerning SPCs entered into force on September 1, 1995. SPCs are granted for Switzerland and for the Principality of Liechtenstein.
- CY : Patent Law 16(I)/98 as amended by Law 21(I)/99 and Patent Regulations and P.I. No. 46/99.
- CZ : Collection of Laws No. 527/1990, Law on Inventions, Industrial Designs and Rationalization Proposals as amended by the Law amending some laws on the protection of industrial property, No. 116/2000.
- DE : Council Regulation (EEC) No. 1768/92 of June 18, 1992, and Amendment to the German Patent Law of March 23, 1993.
- DK : Council Regulation (EEC) No. 1768/92 of June 18, 1992, concerning the creation of a supplementary protection certificate for medicinal products, and the following national legislation: Consolidated Patents Act No. 587 of July 2, 1993, and Order on Patents and Supplementary Protection Certificates No. 1193 of December 23, 1992.
- ES : Council Regulation (EEC) No. 1768/92 of June 18, 1992.
- EE : Patent Act of 1994 as amended in 1999 (the amendments came into force on January 1, 2000) and the Regulations under the Patent Act of 1994.
- FI : Patents Act, Chapter 9a; Patents Decree, Section 52d-52p and Council Regulation (EEC) No. 1768/92 of June 18, 1992.
- FR : Council Regulation (EEC) No. 1768/92 of June 18, 1992.
- GB : Council Regulation (EEC) No. 1768/92 of June 18, 1992, concerning the creation of a Supplementary Protection Certificate for medicinal products.
- IE : Council Regulation (EEC) No. 1768/92 of June 18, 1992, and European Communities (Supplementary Protection Certificate) Regulations, 1993 (S.I. No. 125 1993).
- IT : National and Community laws (Council Regulation (EEC) No. 1768/92 of June 18, 1992).
- JP : Patent Law, Sections 67/2, 67bis, 67ter.
- KR : Patent Law, Sections 89 to 93.
- KZ : The Patent Law of 1999, Astana, Art. 5.
- LU : Council Regulation (EEC) No. 1768/92 of June 18, 1992, and Grand-Ducal Regulations of November 17, 1997, on Patent Procedures and Fees.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.4

- LV : Patent Law of 1995, Articles 7(9) and 31(5).
- MD : Law No. 461-XIII, of May 18, 1995, Art.20.1, on Patents for Invention of Supplementary Protection for pharmaceutical products, and Regulations under that law.
- MX : Law on the Development and Protection of Industrial Property (Article 23), for patents granted under its provisions. SPCs are not granted under the legislation now in force (Industrial Property Law).
- NL : Council Regulation (EEC) No. 1768/92 of June 18, 1992 and the Netherlands Patents Act of 1995 and its Regulations.
- NO : Act No. 9 of December 15, 1967, as amended by Act No. 40 of June 24, 1994, and No. 98 of December 19, 1997 (Chapter 9a, Sections 62a and 62b).
- PT : Council Regulation (EEC) No. 1768/92 of June 18, 1992.
- RO : National legislation regarding SPCs for medicinal and phytopharmaceutical products harmonized with Council Regulation (EEC) No. 1768/92 of June 18, 1992, and Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996.
- SE : Council Regulation (EEC) No. 1768/92 of June 18, 1992.
- US : United States Code (USC), Title 35 Patents, Sections 155, 155A and 156 on Extension of Patent Term: 35 USC§ 155-156 (2000) and Code of Federal Regulations (CFR) Rules of Practice in Patent Cases, Extension of Patent Term: 37 CFR §1710-1785 /2000).

(b) In the field of phytopharmaceutical products

- AT : Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996, and Federal Law on Supplementary Protection Certificates 1996, No. 11/1997.
- AU : Australian Patents Act of 1990 (Sections 70 to 79 and Schedule 1); Australian Patents Regulations of 1991 (Regulation 6.7-6-11).
- BE : Royal Decree of November 8, 1998, concerning applications and grants of supplementary protection certificates for plant protection products (in French: "Arrêté royal du 8 novembre 1998, relatif à la demande et à la délivrance des certificats complémentaires de protection pour les produits phytopharmaceutiques) and Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996, concerning the creation of a supplementary protection certificate for plant protection products.
- CH : Federal Law on Patents for Invention of June 25, 1954 (amended on February 3, 1995). Ordinance on Patents for Invention of October 19, 1977 (amended on May 17, 1995). The amendments concerning SPCs entered into force on September 1, 1995. SPCs are granted for Switzerland and for the Principality of Liechtenstein.
- CY : Patent (Amendment) Law of 2000 [No. 153(I)/2000]; Patent (Amendment) Regulations 2000 [P.I.320/2000].
- CZ : Collection of Laws No. 527/1990, Law on Inventions, Industrial Designs and Rationalization Proposals as amended by the Law amending some laws on the protection of industrial property, No. 116/2000 (an unofficial translation can be found on the Czech Office website: <http://www.upc.cz/>).
- DE : Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996, and Amendment to the German Patent Law of March 23, 1993 (insertion of Sections 16a and 49a).
- DK : Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996, concerning the creation of a supplementary protection certificate for plant protection products.
- EE : Patent Act of 1994, as amended in 1999 (the amendments came into force on January 1, 2000) and the Regulations under the Patent Act of 1994.
- ES : Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996.
- FI : Patents Act, Chapter 9a, Patents Decree, Section 52d-52p and the Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996.
- FR : Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996, for the creation of a supplementary protection certificate for plant protection products.
- GB : Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996.
- IE : Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996.
- IT : National and Community laws (Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996).
- JP : Patent Law, Sections 67/2, 67bis, 67ter.
- KR : Patent Law, Sections 89 to 93.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.5

- KZ : Patent Law of 1999, Astana, Art. 5.
- LU : Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996, and Grand-Ducal Regulation of November 17, 1997, on Patent Procedures and Fees.
- LV : Patent Law of 1995, articles 7(9) and 31(5).
- MD : Law No. 461/1995, on Patents for Invention of Supplementary Protection for pharmaceutical products.
- NL : Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996, and the Netherlands Patents Act of 1995 and its Regulations (Ordinance 1997/42).
- NO : Act No. 9 of December 15, 1967, as amended by Act No. 40 of June 24, 1994, and No. 98 of December 19, 1997 (Chapter 9a, Section 62a) and 62b).
- PT : Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996.
- RO : National legislation regarding SPCs for medicinal and phytopharmaceutical products harmonized with Council Regulation (EEC) No. 1768/92 of June 18, 1992, and Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996.
- SE : Regulation (EC) No. 1610/96 of the European Parliament and of the Council of July 23, 1996.
- US : United States Code (USC), Title 35 Patents, Sections 155, 155A and 156 on Extension of Patent Term: 35 USC§ 155-156 (2000) and Code of Federal Regulations (CFR) Rules of Practice in Patent Cases, Extension of Patent Term: 37 CFR §1710-1785 /2000).

Remarks:

- JP : Phytopharmaceutical products are protected and treated in the same way as medicinal products.

QUESTION 4:

Please give the name of the SPC granted by your Office.

(a) In the field of medicinal products

- AT : Supplementary Protection Certificate (in German: "Ergänzendes Schutzzertifikat").
- AU : No special name given, merely a patent with an extended term of protection.
- BE : Supplementary Protection Certificate for Medicinal Products (in French: "Certificat complémentaire de protection pour les médicaments").
- CH : Supplementary Protection Certificate for Medicinal Products (in French: "Certificat complémentaire de protection pour les médicaments"; in German: "Ergänzendes Schutzzertifikat für Arzneimittel"; in Italian: "Certificato protettivo complementare per medicinali").
- CY : Supplementary Protection Certificate for medicinal products.
- CZ : Supplementary Protection Certificate to Patent (in Czech, "Dodatkové ochranné osvědčení patentu").
- DE : Supplementary Protection Certificate (in German: "Ergänzendes Schutzzertifikat").
- DK : Supplementary Protection Certificate for Medicinal Products (in Danish: "Supplerende beskyttelsescertifikat for lægemidler").
- EE : Supplementary Protection Certificate (in Estonian: "Täiendava Kaiste Tunnistus").
- ES : Supplementary Protection Certificate for Medicinal Products (in Spanish: "Certificado Complementario de Protección para medicamentos").
- FI : Supplementary Protection Certificate for Medicinal Products (in Finnish: "Lääkeaineiden lisäsuojatodistus"; in Swedish: "Tilläggskydd för läkemedel").
- FR : Supplementary Protection Certificate for Medicinal Products (in French: "Certificat complémentaire de protection pour les médicaments").
- GB : Supplementary Protection Certificate.
- IE : Supplementary Protection Certificate.
- IT : Supplementary Protection Certificate.
- JP : No special name given ("Registration of extension of term of patent right").
- KR : Extension of Term of Patent Right.
- LU : Supplementary Protection Certificate for Medicinal Products.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.6

- LV : No special name given.
- MD : Supplementary Protection Certificate.
- MX : They have not been given any special name; a three-year extension of the validity of patents granted under the Law on the Development and Protection of Industrial Property (Article 23) is allowed. SPCs are not granted under the Industrial Property Law currently in force.
- NL : Supplementary Protection Certificate for Medicinal Products, (in Dutch: "aanvullend beschermingscertificaat voor geneesmiddelen").
- NO : Supplementary Protection Certificate (in Norwegian: "Supplerende beskyttelsessertifikat").
- PT : Supplementary Protection Certificate (in Portuguese: "Certificado complementar de protecção para os medicamentos").
- SE : Supplementary Protection for Medicinal Products (in Swedish: "Tilläggskydd för läkemedel").
- US : Certificate Extending Patent Term Under 35 U.S.C. 156.

(b) In the field of phytopharmaceutical products

- AT : Supplementary Protection Certificate ("Ergänzendes Schutzzertifikat").
- AU : No special name given, merely a patent with an extended term of protection.
- BE : Supplementary Protection Certificate for Phytopharmaceutical Products (in French: "Certificat complémentaire de protection pour les produits phytopharmaceutiques").
- CH : Supplementary Protection Certificate for Phytopharmaceutical Products (in French: "Certificat complémentaire de protection pour les produits phytopharmaceutiques"; in German: "Ergänzendes Schutzzertifikat für Pflanzenschutzmittel"; in Italian: "Certificato protettivo complementare per prodotti fitosanitari").
- CY : Supplementary Protection Certificate for Plant Protection Products (in Greek: Συμπληρωματική Πιστοποιητική Προστασίας για τα Φυτοπροστατευτικά προϊόντα).
- CZ : Supplementary Protection Certificate to Patent (in Czech, "Dodatkové ochranné osvědčení patentu").
- DE : Supplementary Protection Certificate (in German: "Ergänzendes Schutzzertifikat").
- EE : Supplementary Protection Certificate (in Estonian: "Täiendava Kaiste Tunnistus").
- ES : Supplementary Protection Certificate for Medicinal Products (in Spanish: "Certificado Complementario de Protección para productos fitosanitarios").
- FI : Supplementary Protection Certificate for Plant Products (in Finnish: "Kasvinsuojeluvälineiden lisäsuojatodistus"; in Swedish: "Tilläggskydd för växtskyddsmedel").
- FR : Supplementary Protection Certificate for Phytopharmaceutical Products (in French: "Certificat complémentaire de protection pour les produits phytopharmaceutiques").
- GB : Supplementary Protection Certificate.
- IE : Supplementary Protection Certificate.
- IT : Supplementary Protection Certificate for Phytopharmaceutical Products.
- JP : No special name given ("Registration of extension of term of patent right").
- KR : Extension of Term of Patent Right.
- LU : Supplementary Protection Certificate for Phytopharmaceutical Products.
- LV : No special name given.
- MD : Supplementary Protection Certificate.
- NL : Supplementary Protection Certificate for Plant Protection Products (in Dutch: "aanvullend beschermingscertificaat voor gewasbeschermingsmiddelen").
- NO : Supplementary Protection Certificate (in Norwegian: "Supplerende beskyttelsessertifikat").
- PT : Supplementary Protection Certificate (in Portuguese: "Certificado complementar de protecção para os produtos fitofarmacêuticos").
- SE : Supplementary Protection for Plant Protection Products (in Swedish: "Tilläggskydd för växtskyddsmedel").
- US : Certificate Extending Patent Term Under 35 U.S.C. 156.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.7

QUESTION 5:

Please specify for which fields of technology or which products an SPC can be obtained (for example, medicinal products, pharmaceutical products, phytopharmaceutical products, herbicides, agro-chemicals, all products subject to regulatory approval for marketing, etc.).

(a) In the field of medicinal products

- AT : Medicinal products.
- AU : Pharmaceutical products including phytopharmaceuticals.
- BE : Medicinal products as defined by Council Regulation (EEC) No. 1768/92.
- CH : Active ingredients or combinations of active ingredients of a medicinal product.
- CY : Medicinal products only.
- CZ : All medicinal products with marketing approval.
- DE : Medicinal products as defined by Council Regulation (EEC) No. 1768/92, Art. 1(a).
- DK : Medicinal products.
- EE : Medicinal products.
- ES : Medicinal products as defined by Council Regulation (EEC) No. 1768/92.
- FI : Medicinal products as defined by Council Regulation (EEC) No. 1768/92.
- FR : Any product protected by a patent which has been granted marketing approval (applicable to medicinal and phytopharmaceutical products).
- GB : Products placed on the market as medicinal products subject to authorization in accordance with Directives 65/65/EEC or 81/851/EEC.
- IE : As defined in Council Regulation (EEC) No. 1768/92.
- IT : Medicinal products.
- JP : Pharmaceutical products, pharmaceutical products for animals, agrochemicals and active ingredients.
- KR : Pharmaceutical products, agrochemicals, herbicides and veterinary drugs.
- KZ : All products for which marketing approval has been given.
- LU : Medicinal products as defined in Council Regulation (EEC) No. 1768/92.
- LV : Medicinal or veterinary products covered by the provisions of laws in force on pharmaceuticals requiring obligatory testing and registration of the product prior to its being marketed in the Republic of Latvia.
- MD : Medicinal products.
- MX : Pharmaceutical products and processes and only for patents granted under the Law on the Development and Protection of Industrial Property. SPCs are not granted under the Industrial Property Law currently in force.
- NL : Medicinal products subject to regulatory approval for marketing.
- NO : Medicinal products and phytopharmaceutical products, including herbicides.
- PT : Medicines.
- SE : Medicinal products.
- US : Human drugs, antibiotic drugs or human biological products (as those terms are used in the US Federal Food Drug, and Cosmetic and the Public Health Services Act), new animal drugs or veterinary biological products (as those terms are used in the US Federal Food, Drug, and Cosmetic and the Virus-Serum-Toxin Act) which are not primarily manufactured using recombinant DNA, recombinant RNA, hybridoma technology, or other processes involving site specific genetic manipulation techniques, including any salt or ester of the active ingredient, as a single entity or in combination with another active ingredient, and any medical device, food additive, or color additive subject to regulation under the Federal Food, Drug, and Cosmetic Act.



(b) In the field of phytopharmaceutical products

- AT : Plant protection products.
- AU : Pharmaceutical products including phytopharmaceuticals.
- BE : Phytopharmaceutical products as defined by Regulation (EC) No. 1610/96.
- CH : Active ingredients or combinations of active ingredients of a phytopharmaceutical product.
- CY : It covers all agricultural medicines including all plant protection products and herbicides.
- CZ : All medicinal phytopharmaceutical products with marketing approval.
- DE : Phytopharmaceutical products as defined by Regulation (EC) No. 1610/96.
- DK : Plant products.
- EE : Plant protection products.
- ES : Phytopharmaceutical products as defined by Regulation (EC) No. 1610/96.
- FI : Plant products as defined in Regulation (EC) No. 1610/96.
- FR : Any product protected by a patent that has been granted marketing approval (applicable to medicinal and phytopharmaceutical products).
- GB : Products placed on the market as plant protection products subject to authorization in accordance with Article 4 of Directive 91/414/EEC.
- IE : As defined in Regulation (EC) No. 1610/96.
- IT : Phytopharmaceutical products.
- JP : Drugs made from plants.
- KR : Pharmaceutical products, agrochemicals, herbicides and veterinary drugs.
- KZ : All products for which marketing approval has been given.
- LU : Phytopharmaceutical products.
- LV : Medicinal or veterinary products covered by the provisions of laws in force on pharmaceuticals requiring obligatory testing and registration of the product prior to its being marketed in the Republic of Latvia.
- MD : Phytopharmaceutical products.
- NL : Plant protection products subject to regulatory approval for marketing.
- NO : Medicinal products and phytopharmaceutical products, including herbicides.
- PT : Phytopharmaceutical products.
- SE : Phytopharmaceutical products.
- US : Human drugs, antibiotic drugs or human biological products (as those terms are used in the US Federal Food Drug, and Cosmetic and the Public Health Services Act), new animal drugs or veterinary biological products (as those terms are used in the US Federal Food Drug, and Cosmetic and the Virus-Serum-Toxin Act) which are not primarily manufactured using recombinant DNA, recombinant RNA, hybridoma technology, or other processes involving site specific genetic manipulation techniques, including any salt or ester of the active ingredient, as a single entity or in combination with another active ingredient, and any medical device, food additive, or color additive subject to regulation under the Federal Food, Drug, and Cosmetic Act.

QUESTION 6:

Does your Office publish or intend to publish the receipt of an application for an SPC? (If "Yes," please attach specimen of a front page of an SPC and/or of announcements regarding SPCs made in an Official Gazette.)

(a) In the field of medicinal products

- Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE, (25)
- No : AP, CN, KZ, MX, MY, OA, US, (7)



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.9

Remarks:

- BE: See Appendix 3.
- CY: Intends to publish the receipts of SPC applications when its system is fully operational.
- FI: For specimen announcements, see FIPO website www.prh.fi link "Patents" - in Patent Gazette under "Tehtyjä lisäsuojatodistushakemuksia-Ingivna ansökningar om tillägsskydd".
- GB: See Appendix 11.
- IT: The Office does publish the receipts of SPC applications.
- LU: A notice is published either of the filing and refusal of an SPC application or of the filing and grant of an SPC.
- MD: Data related to the filing or refusal of an SPC application are published.
- PT: The application and mention of the grant.
- RO: The Office intends to publish the receipts of SPC applications when the system will be operational.
- US: However, the Food and Drug Administration publishes a determination related to the filing of an application for patent term extension, including the approval date of the product and the new drug application (or other application) number. See the attached Federal Register Notice (Appendix 21).

(b) In the field of phytopharmaceutical products

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, RO, SE (24)

No: AP, CN, KZ, MX, MY, OA, US (7)

Remarks:

- BE: See Appendix 3.
- CY: Intends to publish the receipts of SPC applications when its system is fully operational.
- GB: See Appendix 11.
- JP: Phytopharmaceutical products are protected and treated in the same way as medicinal products.
- MD: Data related to the filing or refusal of an SPC application are published.
- PT: The application and mention of the grant.
- RO: The Office intends to publish the receipt of SPC applications in the Bulletin when the system will be operational.
- US: However, the Food and Drug Administration publishes a determination related to the filing of an application for patent term extension, including the approval date of the product and the new drug application (or other application) number. See the attached Federal Register Notice (Appendix 21).

QUESTION 7:

If your reply to question 6 is "Yes," please state the minimum elements that a publication must contain

(a) In the field of medicinal products

- (i) Number assigned to receipt of the application

Yes: AT, AU, CH, CZ, BE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (23)

No: CY, DE (2)

Remarks:

AU: Application number is identical to patent number.

DE: See comment under question (viii).

- (ii) Date of receipt

Yes: AT, BE, CH, CZ, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO (21)

No: AU, CY, DE, SE (4)



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.10

Remarks:

CY : See comment under question 6(a).

DE : See comment under question (viii).

(iii) Name and address of the applicant

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (25)

Remarks:

AU : Name but not address of applicant is published.

(iv) Number of the basic patent

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (25)

(v) Title of the invention

Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, LV, MD, NL, NO, PT, RO, SE (22)

No : AU, JP, KR (3)

(vi) Number of any marketing authorization, including the product identified in the authorization

Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (24)

No : AU (1)

Remarks:

AT : The Office publishes the date and number of the first authorization to market the product in Austria as a medicinal product and the date, country and number of the first such authorization in the EEA.

BE : The Office publishes data concerning the placing of the product on the market in Belgium.

CH : The Office publishes the number and date of the first authorization to market the product as a medicinal product in Switzerland and Liechtenstein.

DE : The Office publishes the date and number of the first authorization to market the product in Germany and, if different, the country, number and date of the first authorization to market the product in the EEC.

ES : The number of the first authorization to market the product in Spain and in the European Union.

FI : The Office plans to publish data regarding the first authorization to market the product in Finland.

FR : The Office publishes the number and date of the first authorization to market the product in France as a medicinal product and number and date of the first authorization to market the product in the EEC as a medicinal product.

GB : The Office publishes the number(s) and date(s) of the first authorization in the United Kingdom, and where relevant, the number(s) and date(s) of the first authorization in the community.

IE : Irish market authorization, and where relevant the number and date of the first authorization to market the product in the Community.

IT : The Office publishes the number and date of the first authorization to market the product in Italy as a medicinal product and number and date of the first authorization to market the product in the EEC as a medicinal product.

JP : In addition to the authorization and to the product identified therein, the Japanese Office gives information on the law under which the authorization was obtained, on the product and on the extent of its use.

LU : The Office publishes the number and date of the first authorization to market the product in Luxembourg as a medicinal product, and number and date of the first authorization to market the product in the EEC as a medicinal product.

NL : Number of the first relevant authorization in the Netherlands and, where different, the number of the first relevant authorization concerned in the EC.

NO : The Office intends to publish, where applicable, the number and date of the first authorization to market the product in the EEC.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.11

- (vii) Date of the authorization
Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, MD, NL, NO, PT, RO, SE (21).
No: AU, JP, KR, LV (4)

Remarks

- AT : See explanation given under question 7(a)(vi).
FR : See explanation given under question 7(a)(vi).
GB : See explanation given under question 7(a)(vi).
IT : See explanation given under question 7(a)(vi).
LU : The Office mentions the product as identified in the authorization to market the product in Luxembourg.
NL : See explanation given under question 7(a)(vi).

- (viii) Other elements (please specify)

- AT : The publication contains also the following elements: the application number, the application date and date of grant of the basic patent, its IPC classification symbols, its language (if it is a European patent), the PCT application number (if applicable), the priority of the basic patent (if applicable) and the inventor's name (if applicable).
BE : Number and date of the first authorization to market the product in the EEC as a medicinal product.
CH : The Office also publishes a designation of the product covered by the authorization to market together with the name and address of the representative where applicable.
CZ : Product name.
DE : In addition to the minimum elements provided for in the ECC Regulation, the German Patent and Trademark Office publishes also the IPC main class symbol of the basic patent and the application number of the SPC.
DK : Including the EEA authorization (number and date) and the number in the Community Register of Medicinal Products.
EE : Identification data for the product specified in the authorization.
ES : Name of the product that has received the authorization.
FI : Name and address of the representative.
FR : Filing date, application number and date of grant of the basic patent.
GB : The product name.
IE : Where the authorization to market the product in Ireland is not the first authorization in the EEC, the number and date of that first authorization are also published.
IT : Name and address of the representative, filing date and date of grant.
JP : The Office publishes information regarding the extension of the term of protection of the patent.
KR : Claims relating to the product authorized. The product should also be identified in the claims.
LU : The Office names the product as identified in the authorization to market the product in Luxembourg.
NL : Name and address of the agent, if any, and name of the active ingredient as mentioned in the first relevant authorization in the Netherlands.
SE : Where relevant, the number and date of the first authorization to market the product in the EEC.

(b) In the field of phytopharmaceutical products

- (i) Number assigned to receipt of the application
Yes: AT, BE, CH, CZ, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (22)
No: CY, DE (2)

Remarks:

- AU : Application number is identical to patent number.
DE : See comment under question (viii).



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.12

- (ii) Date of receipt
Yes: AT, BE, CH, CZ, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, PT, RO (20)
No: AU, CY, DE (3)

Remarks:
DE : See comment under question (viii).
- (iii) Name and address of the applicant
Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (25)

Remarks:
AU : Name but not address of applicant is published.
- (iv) Number of the basic patent
Yes: AT, AU, CH, CY, CZ, BE, DE, DK, EE, ES, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (24)
- (v) Title of the invention
Yes: AT, CZ, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, LV, MD, NL, NO, PT, RO, SE (23)
No: AU, JP, KR (3)
- (vi) Number of any authorization to market the product, including the product identified in that authorization
Yes: AT, CZ, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (25)
No: AU (1)

Remarks:
AT : The Office publishes the date and number of the first authorization to market the product in Austria as a plant protection product and the date, country and number of the first such authorization in the EEA.
CH : The Office publishes the date and number of the first authorization to market the product as a phytopharmaceutical product in Switzerland and Liechtenstein.
DE : The German Patent and Trademark Office publishes the date and number of the first authorization to market the product in Germany and, if different, the country, number and date of the first authorization to market the product in the EEC.
ES : The number of the first authorization to market the product in Spain and in the European Union.
GB : The Office publishes the number(s) and date(s) of the first authorization in the United Kingdom, and where relevant, the number(s) and date(s) of the first authorization in the community.
IE : Irish market authorization, and where relevant, the number and date of the first authorization to market the product in the Community.
JP : In addition to the authorization and to the product identified therein, the Japanese Office gives information on the law under which the authorization was obtained, on the product and on the extent of its use.
LU : The Office publishes the number and date of the first authorization to market the product in Luxembourg as a medicinal product, and number and date of the first authorization to market the product in the EEC as a medicinal product.
NL : Number of the first relevant authorization in the Netherlands and, where different, the number of the first relevant authorization in the EC.
- (vii) Date of the authorization
Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, MD, NL, NO, PT, RO, SE (21)
No: AU, JP, KR, LV (4)

Remarks:
AT : See explanation given under question 7(b) (vi).
DE : See explanation given under question (vi) above.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.13

- LU : The Office mentions the product as identified in the authorization to market the product in Luxembourg.
- (viii) Other elements (please specify)
- AT : See information given under question 7 (a) (vi).
- BE : Number and date of the first authorization to market the product in the EEC as a phytopharmaceutical product.
- CH : The Office also publishes a designation of the product covered by the authorization to market together with the name and address of the representative where applicable.
- CZ : Product name.
- DE : In addition to the minimum elements prescribed by the EEC Regulation, the German Patent Office publishes also the IPC main class symbol of the basic patent and the application number of the SPC.
- DK : Including the EEA authorization (number and date) and the number in the Community Register of Medicinal Products.
- EE : Identification data for the product specified in the authorization.
- ES : Name of the product that has received the authorization.
- FI : Name and address of the representative.
- FR : Filing date, application number and date of grant of the basic patent.
- GB : The product name.
- IT : Name and address of the representative, filing date and date of grant.
- KR : Claims relating to the product authorized. The product should also be identified in the claims.
- LU : The Office mentions the product as identified in the authorization to market the product in Luxembourg.
- NL : Name and address of the agent, if any, and name of the active ingredient as mentioned in the first relevant authorization in the Netherlands.
- SE : Where relevant, the number and date of the first authorization to market the product in the EEC.

QUESTION 8:

Does your Office publish or intend to publish the fact that an SPC has been granted?
(If "Yes," please attach specimen of a front page of an SPC and/or of announcement regarding the grant of SPCs made in an Official Gazette.)

(a) In the field of medicinal products

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, MX, NL, NO, PT, RO, SE, US (27)

No : MY, OM (2)

Remarks:

BE : See Appendix 3.

FI : For specimen announcement, see FIPO website www.prh.fi link "Patents"- in Patent Gazette under "Myönnettyjä lisäsuojatodistuksia-Beviljade tilläggsskydd".

GB : See Appendix 11.

MX : In the case of SPCs for patents granted under the old Law on the Development and Protection of Industrial Property the extension of validity is published in the journal "La Gaceta" (Article 8 of that Law).

RO : The Office intends to publish the grant of SPCs in the Bulletin when the system will be operational.

US : See sample of the Official Gazette notice attached to this Survey as Appendix 21.



(b) In the field of phytopharmaceutical products

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE, US (26)

No : MY, OM (2)

Remarks:

BE : See Appendix 3.

DK : Granted SPCs are not published.

GB : See Appendix 11.

RO : The Office intends to publish the grant of SPCs in the Bulletin when the system will be operational.

US : See Appendix 21.

QUESTION 9:

If your reply to question 8 is "Yes," please state the minimum elements that a publication must contain

(a) In the field of medicinal products

(i) Registration number assigned to the granted SPC

Yes: AT, AU, BE, CH, CZ, DK, EE, ES, FI, FR, GB, IE, IT, JP, LU, LV, MD, NL, NO, PT, RO, SE (22)

No : CY, DE, KR, US (4)

Remarks:

AU : Application number is identical to patent number.

BE : No special registration number is given; the number of the application for an SPC is used.

CH : The Office uses the basic patent number with an addition ("CNNNNNN").

IE : No special registration number is given; the number of the application for an SPC is used.

IT : No special registration Number is given; the number of the application for an SPC is used.

JP : No special registration number is given; the patent number of the basic patent is used.

US : No specific registration number is given; the publication number of the patent is used.

(ii) Date of the registration of the granted SPC

Yes: AT, BE, CH, CZ, EE, ES, FR, GB, IE, IT, JP, KL, LV, MD, NO, PT, RO, SE, US (19)

No : AU, CY, DE, DK, FI, KR, LU, NL (8)

Remarks:

AT : The Office publishes the actual date of grant.

FR : The Office specifies in its Official Gazette the expiry date of the SPC.

GB : The Office publishes the actual date of grant, which is specified on the certificate.

IT : The Office publishes the actual date of grant, which is specified on the certificate.

NL : The Office publishes in the Official Gazette the date on which the SPC enters into force.

(iii) Name and address of the holder of the SPC

Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, MX, NL, NO, PT, RO, SE, US (26)

No : AU (1)

Remarks:

AU : Name but not address of applicant is published.

US : But the United States Patent and Trademark Office publishes the name only.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.15

(iv) Number of the basic patent

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, MX, NL, NO, PT, RO, SE, US (27)

Remarks:

IT : Name and address of the representative, filing date and date of grant.

(v) Title of the invention

Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, LV, MD, MX, NL, NO, PT, RO, SE, US (24)

No : AU, JP, KR (3)

(vi) Number of any marketing authorization, including the product identified in that authorization

Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LV, MD, NL, NO, RO, SE (22)

No : AU, US (2)

Remarks:

AT : See explanations given under question 7(a)(vi).

CH : The Office publishes the number and date of the first authorization to market the product as a medicinal product in Switzerland and Liechtenstein.

DE : The German Patent and Trademark Office publishes the date and number of the first authorization to market the product in Germany and, if different, the country, number and date of the first authorization to market the product in the EEC.

ES : The number of the first authorization to market the product in Spain and in the European Union.

FI : As in question 7(a)(vi).

FR : As in question 7(a)(vi).

GB : The Office publishes the number(s) and date(s) of the first authorization in the United Kingdom, and where relevant, the number(s) and date(s) of the first authorization in the community.

IE : Irish market authorization, and where relevant, the number and date of the first authorization to market the product in the Community.

IT : As in question 7(a)(vi).

JP : No special registration number is given; the patent number of the basic patent is used.

LU : As in question 7(a)(vi).

NL : Number of the first authorization in the Netherlands and, where different, the number of the first relevant authorization in the EC.

SE : As in question 7(a)(vi).

(vii) Date of the authorization

Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, LV, MD, NL, NO, PT, RO, SE (22)

No : AU, JP, KR, US (4)

(viii) Duration of the SPC

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, MD, NL, NO, PT, RO, US (23)

No : LV, SE (2)

Remarks:

AT : The duration is identified by the expiry date of the maximum period.

CH : The Office specifies the expiry date of the SPC.

ES : Expiry date of validity.

IE : The duration is identified by the expiry date of the maximum period.

LV : The duration is identified by the expiry date of the SPC.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.16

- (ix) Other elements, e.g. patent classification, product name (please specify)
- AT : See explanations given under question 7(a) (viii).
- CH : The Office also publishes a designation of the product covered by the authorization to market, the filing date of the application and the name and address of the representative where applicable.
- CZ : Product name.
- DE : In addition to the minimum elements prescribed by the EEC Regulation the German Patent and Trademark Office publishes also the IPC main class symbol of the basic patent and the application number of the SPC.
- EE : Identification data for the product specified in the authorization.
- ES : Name of the product that has received the authorization.
- FI : Number and date of the corresponding application, name and address of the representative.
- FR : Filing date, application number and date of grant of the basic patent.
- GB : The product name.
- IE : Where necessary, the fact that the application has been rejected is also published.
- IT : Name and address of the representative, filing date and date of grant.
- KR : Product name approved by authorization.
- LV : Product name.
- NL : Name and address of the agent, if any, and name of the product for which the SPC has been granted.
- SE : Where relevant number and date of the first authorization to market the product in the EEC.
- US : Patent grant date, applicant, owner of record, patent classification and product trade name.

(b) In the field of phytopharmaceutical products

- (i) Registration number assigned to the granted SPC
- Yes: AT, AU, BE, CH, CZ, DK, EE, ES, FI, FR, GB, IE, IT, JP, LU, LV, NL, MD, NO, PT, RO, SE (22)
- No: CY, DE, KR, US (4)

Remarks:

- AU : Application number is identical to patent number.
- BE : No special registration number is given; the number of the application for an SPC is used.
- CH : The Office uses the basic patent number with an addition ("CNNNNNN").
- IE : No special registration number is given; the number of the application for an SPC is used.
- JP : No special registration number is given; the number of the basic patent is used.
- US : No specific registration number is given; the publication number of the patent is used.

- (ii) Date of registration of the granted SPC
- Yes: AT, BE, CH, CZ, EE, ES, FR, GB, IE, IT, JP, LV, MD, NO, PT, RO, US (17)
- No: AU, CY, DE, DK, FI, KR, NL, SE (8)

- (iii) Name and address of the holder of the SPC
- Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE, US (25)
- No: AU (1)

Remarks:

- AU : Name but not address of applicant is published.
- US : But the United States Patent and Trademark Office publishes the name only.

- (iv) Number of the basic patent
- Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE, US (26)

Remarks:

- IT : Name and address of the representative, filing date and date of grant.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.17

- (v) Title of the invention
Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, LU, LV, MD, NL, NO, PT, RO, SE, US (23)
No: AU, JP, KR (3)

- (vi) Number of any market authorization, including the product identified in the authorization
Yes: AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LV, MD, NL, NO, PT, RO, SE (23)
No: AU, US (2)

Remarks

- AT : See explanations given under question 7(b)(vi).
CH : The Office publishes the number and date of the first authorization to market the product as a phytopharmaceutical product in Switzerland and Liechtenstein.
DE : The German Patent and Trademark Office publishes the date and number of the first authorization to market the product in Germany and, if different, the country, number and date of the first authorization to market the product in the EEC.
ES : The number of the first authorization to market the product in Spain and in the European Union.
GB : The Office publishes the number(s) and date(s) of the first authorization in the United Kingdom, and where relevant, the number(s) and date(s) of the first authorization in the community.
IE : Irish market authorization, and where relevant, the number and date of the first authorization to market the product in the Community.
JP : No special registration number is given; the number of the basic patent is used.
NL : The number of the first relevant authorization in the Netherlands and, where different, the number of the first relevant authorization in the EC.

- (vii) Date of the authorization
Yes: AT, BE, CH, CY, CZ, DE, EE, ES, FI, FR, GB, IE, IT, LU, LV, MD, NL, NO, PT, RO, SE (21)
No: AU, JP, KR, US (4)

Remarks:

- DE : See explanation given under question (vi) above.

- (viii) Duration of the SPC
Yes: AT, AU, CH, CY, CZ, BE, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, MD, NL, NO, PT, RO, US (23)
No: LV, SE (2)

Remarks

- AT : The duration is identified by the expiry date of the maximum period.
CH : The Office specifies the expiry date of the SPC.
ES : Expiry date of validity.
IE : The duration is identified by the expiry date of the maximum period.
LV : The duration is identified by the expiry date of the SPC.

- (ix) Other elements, e.g. patent classification, product name (please specify)
AT : See information given under question 7(a)(viii).
CH : The Office also publishes a designation of the product covered by the authorization to market, the filing date of the application and the name and address of the representative where applicable.
CZ : Product name.
DE : In addition to the minimum elements prescribed by the EEC Regulation, the German Patent and Trademark Office publishes also the IPC main class symbol of the basic patent and the application number of the SPC.
EE : Identification data for the product specified in the authorization.
ES : Name of the product that has received the authorization.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.18

- FI : Number and date of the corresponding application, name and address of the representative.
- FR : Filing date, application number and date of grant of the basic patent.
- GB : The product name.
- IE : Where necessary, the fact that the application has been rejected is also published.
- IT : Name and address of the representative, filing date and date of grant.
- KR : Product name approved by authorization.
- LV : Product name.
- NL : Name and address of the agent, if any, and name of the product for which the SPC has been granted.
- SE : Where relevant, the number and date of the first authorization to market the product in the EEC.
- US : Patent grant date, applicant, owner of record, patent classification, product trade name.

QUESTION 10:

In what form does your Office make or intend to make the publications referred to in questions 6 and 8?

(a) In the field of medicinal products

(i) As regards applications for SPCs

(a) As part of an Official Gazette?

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (25)

No : US (1)

Remarks:

BE : Publication in the "Recueil des brevets d'invention" (monthly publication).

CH : The Office also publishes a notice of SPC applications that have been refused.

LU : Publication of a notice in the Official Gazette.

(b) By publishing the application?

Yes: AT, AU, BE, CH, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, SE, US (24)

Remarks:

JP : Announcement is made in the Official Gazette.

(c) By laying the application open to public inspection?

Yes: CH, CZ, DK, EE, FI, FR, GB, IE, IT, LU, MD, NL, NO, PT, US (15)

No : AT, AU, BE, DE, ES, JP, KR, LV, SE (9)

Remarks:

AU : The announcement in the Official Gazette states that the application is open to public inspection.

CH : Only after notice of the application has been published.

LU : The file may be consulted as from the date of grant (=publication date) of the SPC.

NL : The application filed and correspondence between the Netherlands Industrial Property Office and the applicant are laid open to public inspection.

(d) Through online databases (or the Office's website)?

Yes: AT, BE, CH, CZ, DE, DK, ES, FI, FR, GB, IE, IT, KR, NL (14)

No : AU, EE, JP, LV, MD, NO, PT, SE, US (9)



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.19

Remarks:

- AU : The internal database of the Office (PATADMIN) shows that an application has been made.
- BE : Belgian Patent and SPC Registry, public part accessible online (not through the Internet).
- CH : All data on SPCs are contained in the internal BAGIS database and are accessible on the Office's Website through the Online patentregister Swissreg after grant.
- DE : Bibliographic data and legal status information are obtainable from the Patent Register and the PATDPA database.
- FI : The Patent Gazette is available on the FIPO website.
- IE : Certain details are entered in the PTOLEMY database under the register entry for the corresponding basic patent—the Register entry is viewable on the public search system of the Office.

- (e) By delivery of the copy application on request?

Yes: CH, CZ, DK, EE, FI, FR, GB, IE, IT, KR, LU, MD, NL, PT, US (15)

No: AT, AU, BE, DE, ES, JP, LV, NO, SE (9)

Remarks:

- CH : Reference is made to the comment under Question 10(a)(i)(c).
- DE : Copies of SPC applications are available in the course of a file inspection.
- KR : Copy delivery is possible for certain parts of the file that are available to the public.
- US : Copies are provided upon payment of a fee.

- (ii) As regards granted SPCs

- (a) As part of an Official Gazette?

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, MX, NL, NO, PT, RO, SE, US (27)

Remarks:

- BE : Publication in the "Recueil des brevets d'invention" (monthly publication).
- LU : Publication of a notice in the Official Gazette.
- MX : Only in the case of patents granted under the Law on the Development and Protection of Industrial Property.

- (b) By publishing the SPC?

Yes: BE, US (2)

No: AT, AU, CH, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, SE (22)

Remarks:

- JP : Announcement is made in the Official Gazette.

- (c) By laying the SPC open to public inspection?

Yes: BE, CH, CZ, DK, EE, FI, GB, IE, IT, LU, MD, NL, NO, PT, US (15)

No: AT, AU, DE, ES, FR, JP, KR, LV, SE (9)

Remarks:

- BE : Consultation is possible for certain parts of the file that are available to the public.
- LU : The file may be consulted as from the date of grant (= publication date) of the SPC.
- NL : The application as filed, correspondence exchanged between the Netherlands Industrial Property Office and the applicant, and the granted SPC are laid open to public inspection.

- (d) Through online databases (or the Office's website)?

Yes: AT, BE, CH, CZ, DE, DK, ES, FI, FR, GB, IE, IT, LV, NL, US (15)

No: AU, JP, MD, NO, PT, SE (6)



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.20

Remarks:

- AU : The internal database of the Office (PATADMIN) shows that an extension of the term of protection has been granted.
- BE : Belgian Patent and SPC Registry, public part accessible online (not through the Internet).
- CH : All data on SPCs are contained in the internatl BAGIS database and are accessible on the Office's Website through the Online patentregister Swissreg after grant.
- DE : Bibliographic data and legal status information are obtainable from the Patent Register and the PATDPA database.
- FI : The Patent Gazette is available on the FIPO website.
- IE : Certain details are entered in the PTOLEMY database under the Register entry for the corresponding basic patent—the Register entry is viewable on the public search system of the Office.
- US : SPC and Official Gazette Notice are available on USPTO's web site.

- (e) By delivery of a copy of the SPC on request?

Yes: AT, BE, CH, CZ, DK, EE, FI, FR, GB, IE, IT, LU, MD, NL, PT, US (16)

No : AU, DE, ES, JP, LV, NO, SE (7)

Remarks:

- AT : Copy delivery is possible for certain parts of the file that are available to the public.
- BE : Copy delivery is possible for certain parts of the file that are available to the public.
- DE : Copies of SPC files are available in the course of a file inspection.

(b) In the field of phytopharmaceutical products

- (i) As regards applications for SPCs

- (a) As part of an Official Gazette?

Yes: AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE (25)

No : US (1)

Remarks:

- BE : Publication in the "Recueil des brevets d'inventin" (monthly publication).
- CH : The Office also published a notice of SPC applications that have been refused.
- LU : Publication of a notice in the Official Gazette.

- (b) By publishing the application?

Yes: JP (1)

No : AT, AU, BE, CH, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, KR, LU, LV, MD, NL, NO, PT, SE, US (23)

Remarks:

JP : Announcement is made in the Official Gazette.

- (c) By laying the application open to public inspection?

Yes: CH, CZ, DK, EE, FI, FR, GB, IE, IT, LU, MD, NL, NO, PT, US (15)

No : AT, AU, BE, DE, ES, JP, KR, LV, SE (9)

Remarks:

- AU : The announcement in the Official Gazette states that the application is open to public inspection.
- LU : The file may be consulted as from the date of grant (= publication date) of the SPC.
- NL : The application as filed and correspondence exchanged between the Netherlands Industrial Property Office and the applicant are laid open to public inspection.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.21

(d) Through online databases (or the Office's website)?

Yes: AT, BE, CH, CZ, DE, DK, ES, FI, FR, GB, IE, IT, KR, NL (14)

No : AU, EE, JP, LV, MD, NO, PT, SE, US (9)

Remarks:

AU : The internal database of the Office (PATADMIN) shows that an extension of the term of protection has been granted.

BE : Belgian Patent and SPC Registry, public part accessible online (not through the Internet).

CH : All data on SPCs are contained in the internal BAGIS database and are accessible on the Office's Website through the Online Patentregister Swissreg after grant.

DE : Bibliographic data and legal status information are obtainable from the Patent Register and the PATDPA database.

FI : The Patent Gazette is available on the FIPOI website.

IE : Certain details are entered in the PTOLEMY database under the Register entry for the corresponding basic patent—The Register entry is viewable on the public search system of the Office.

(e) By delivery a copy of the application on request?

Yes: CH, CZ, DK, EE, FI, FR, GB, IE, IT, KR, LU, MD, NL, PT, US (15)

No : AT, AU, BE, DE, ES, JP, LV, NO, SE (9)

Remarks:

CH : Reference is made to the comment under Question 10(a)(i)(c).

DE : Copies of SPC applications are available in the course of a file inspection.

KR : Copy delivery is possible for certain parts of the file that are available to the public.

US : Copies are provided upon payment of a fee.

(ii) As regards granted SPCs

(a) As part of an Official Gazette?

Yes: AT, AU, BE, CH, CY,CZ, DE, DK, EE, ES, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE, US (25)

Remarks:

BE : Publication in the "Recueil des brevets d'invention" (monthly publication).

CH : The Office also publishes a notice of SPC applications that have been refused.

LU : Publication of a notice in the Official Gazette.

(b) By publishing the SPC?

Yes: BE, JP, US (3)

No : AT, AU, CH, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, KR, LU, LV, MD, NL, NO, PT, SE (21)

Remarks:

JP : Announcement is made in the Official Gazette.

(c) By laying the SPC open to public inspection?

Yes: BE, CH, CZ, DK, EE, FI, FR, GB, IE, IT, LU, MD, NL, NO, PT, US (16)

No : AT, AU, DE, ES, JP, KR, LV, SE (8)

Remarks:

BE : Consultation is possible for certain parts of the file that are available to the public.

LU : The file may be consulted as from the date of grant (=publication date) of the SPC.

NL : The application as filed, the correspondence between the Netherlands Industrial Property Office and the applicant, and the granted SPC are laid open to public inspection.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.22

(d) Through online databases (or the Office's website)?

Yes: AT, BE, CH, CZ, DE, DK, ES, FI, FR, GB, IE, IT, NL, US (14)

No: AU, EE, JP, LV, MD, NO, PT, SE (8)

Remarks:

AU : The internal database of the Office (PATADMIN) shows that an extension of the term of protection has been granted.

BE : Belgian Patent and SPC Registry, public part accessible online (not through the Internet).

CH : All data on SPCs are contained in the internal BAGIS database and are accessible on the Office's Website through the Online Patentregister Swissreg after grant.

DE : Bibliographic data and legal status information are obtainable from the Patent Register and the PATDPA database.

FI : The Patent Gazette is available on the FIPO website.

IE : Certain details are entered in the PTOLEMY database under the Register entry for the corresponding basic patent—the Register entry is viewable on the public search system of the Office.

US : SPC and Official Gazette Notice are available on USPTO's Website.

(e) By delivery of a copy of the SPC on request?

Yes: AT, BE, CZ, DK, EE, FI, FR, GB, IE, IT, LU, MD, NL, PT, US (15)

No: AU, DE, ES, JP, LV, NO, SE (7)

Remarks:

BE : Copy delivery is possible for certain parts of the file that are available to the public.

CH : Regerence is made to the comment under Question 10(a)(i)(c).

DE : Copies of SPC files are available in the course of a file inspection.

QUESTION 11:

If your Office enters or intends to enter data from the documents relating to SPCs in online databases (internal or commercial), please give the name(s) of the database(s) and specify the bibliographic data elements:

(a) In the field of medicinal products

(i) Name(s) of database(s)

AT : The Office's SPC Register ("Schutzcertifikatsregister") contains all data elements specified under question 9.

AU : PATADMIN (internal database).

CH : BAGIS (internal database only); Swissreg (Online Patent Register on Office's Website); INPADOC (commercial).

CY : Not yet available.

CZ : Czech Patent Database (Internet).

DE : (i) Patent Register, (ii) PATDPA (via STN International).

DK : INPADOC.

ES : SIDATEX.

FI : INPADOC.

FR : (i) FPAT, (ii) EPAT.

GB : RSPC, this is the internal database for SPCs which has been made available on the Patent Office website: <http://webdb2.patents.gov.uk/rspc/>.

IE : (i) PTOLEMY (internal database), (ii) PTOLEMY Public Search System.

IT : The Office has only an internal line, with the bibliographic data elements mentioned in paragraph (ii) below.

JP : Data are included in an internal database (no name given).



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.23

- KR : KIPO Patent Term Extension Database.
- MD : Patent Database.
- NL : Computerized Register (in Dutch: "Het Octrooiregister") to be found on the website of the Netherlands Industrial Property Office.
- RO : Data will be included in an internal database.
- US : (i) Patent Term Extension, (ii) USPTO Web Patent Database, SPC (iii) Freedom of Information Act Reading Room, Notice of Final Determination.
- (ii) Bibliographic data elements
- AT : The Office's SPC Register ("Schutzcertifikatsregister") contains all data elements specified under question 9.
- AU : Application number, serial number, extension status, date of lodgment of extension application, market authorization date, extended expiry date, date of acceptance of extension, date of grant of extension, date of refusal of extension, date of withdrawal of extension, dates of advertisement of lodgment, acceptance, grant, withdrawal and refusal of the application for extension, date of filing of opposition, service address.
- CH : Application number of SPC, application number of basic patent, title of invention, name and address of SPC holder, number/date of authorization and name of product, IPC main class symbol, duration of the SPC.
- CZ : See information given under questions 7 and 9.
- DE : Application number of SPC, application number of basic patent, title of invention, name and address of SPC holder, number/date of authorization and name of product, IPC main class symbol, duration of the SPC.
- ES : See information given under questions 7 and 9.
- FR : Same data as those published in the Official Gazette.
- GB : See Appendix 11, pages 1 and 2, from the Patents and Designs Journal.
- IE :
 - Application number- identical to the grant publication number;
 - whether application is for medicinal or plant protection patent;
 - date of application;
 - date of publication of application;
 - name and address of applicant;
 - basic patent;
 - date of expiry of patent;
 - title of patent;
 - Irish market authorization number, date of grant, identity of product authorized, legal provision of authorization;
 - community market authorization, country, date of grant, identity of product authorized, legal provision of the authorization;
 - product identity;
 - address for service;
 - application status;
 - date of grant;
 - date of publication of grant;
 - renewal fees.
- IT :
 - Application number-identical to the grant publication number;
 - filing date;
 - owner;
 - representative;
 - date of grant;
 - product (name);
 - references of the basic patent;
 - ◊ title;
 - ◊ application date;
 - ◊ grant date;
 - ◊ publication number;
 - ◊ Italian AMM (marketing authorization): number, date of grant;
 - ◊ community AMM: country, number, date of grant;
 - ◊ status (active, idle, withdrawn);
 - ◊ dates:
 - of entry into force;
 - of protection period.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.24

- JP : Date of application, number of application, date of registration, term of extension, further data as specified in replies to questions 7 and 9 above.
- KR : See elements specified in reply to questions 7 and 9 above.
- MD : Same elements as specified in replies to questions 7 and 9 above.
- NL : Same elements as specified in replies to questions 7 and 9 respectively. In addition, the date on which the SPC was granted or on which the application was rejected or withdrawn is mentioned.
- US : See elements specified in reply to question 10 above.

(b) In the field of phytopharmaceutical products

- (i) Name(s) of database(s)
 - AT : The Office's SPC Register ("Schutzsertifikat") contains all data elements specified under question 9.
 - AU : PATADMIN (internal database).
 - CH : BAGIS (internal database only); Swissreg (Online Patent Register on Office's Website); INPADOC (commercial).
 - CY : Not yet available.
 - CZ : Czech Patent Database (Internet).
 - DE : (i) Patent Register, (ii) PATDPA (via STN International).
 - DK : INPADOC.
 - ES : SIDATEX.
 - FI : INPADOC.
 - FR : (i) FPAT, (ii) EPAT.
 - GB : RSPC, this is the internal database for SPCs which has been made available on the Patent Office website: <http://www.webdb2.patents.gov.uk/rspc>.
 - IE : PTOLEMY (internal database) and PTOLEMY Public Search System.
 - IT : See answer to Question 11(a)(i).
 - JP : Data are included in an internal database (no name given).
 - KR : KIPO Patent Term Extension Database.
 - MD : Patent Database.
 - NL : Computerized Register (in Dutch: "Het Octrooiregister") to be found on the website of the Netherlands Industrial Property Office.
 - RO : Data will be included in an internal database.
 - US : (i) Patent Term Extension, (ii) USPTO Web Patent Database, SPC (iii) Freedom of Information Act Reading Room, Notice of Final Determination.
- (ii) Bibliographic data elements
 - AT : The Office's SPC Register ("Schutzsertifikatsregister") contains all data elements specified under question 9.
 - AU : Application number, serial number, extension status, date of lodgment of extension application, market authorization date, extended expiry date, date of acceptance of extension, date of grant of extension, date of refusal of extension, date of withdrawal of extension, dates of advertisement of lodgment, acceptance, grant, withdrawal and refusal of the application for extension, date of filing of opposition, service address.
 - CH : Application number of SPC, application, number of basic patent, title of invention, name and address of SPC holder, number/date of authorization and name of product, IPC main class symbol, duration of the SPC.
 - CZ : See information given under questions 7 and 9.
 - DE : Application number of SPC, application number of basic patent, title of the invention, name and address of SPC holder, number/date of authorization and name of product, IPC main class symbol, duration of the SPC.
 - ES : See information given under questions 7 and 9.
 - FR : Same data as those published in the Official Gazette.
 - GB : See Appendix 11, pages 1 and 2, from the Patents and Designs Journal.
 - IE : See answer to Question 11(a)(ii).



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.25

- IT : See answer to Question 11(a)(ii).
- JP : Date of application, number of application, date of registration, term of extension, further data as specified in the replies to questions 7 and 9 above.
- KR : See elements specified in reply to questions 7 and 9 above.
- MD : Same elements as specified in replies to questions 7 and 9 above.
- NL : Same elements as specified in replies to questions 7 and 9 respectively. In addition, the date on which the SPC was granted or on which the application was rejected or withdrawn is mentioned.
- US : See elements specified in reply to question 10 above.

QUESTION 12:

If your Office assigns or intends to assign specific application and/or registration numbers to SPCs, please give details.

(a) In the field of medicinal products

- (i) Concerning the numbering system for applications for SPCs
- AT : The application number and the registration number are prefixed with "SZ" followed by a serial number, which restart at 1 every year, and the four-digit number of the year (SZ NNNN/YYYY).
- AU : No specific numbering system is applied (see replies to questions 7 and 9).
- BE : Before 2000: 09Y C XXXX, since 2000: 2xxxC/XXX.
- CH : The Office uses the basic patent number with an addition ("CNNNNNN").
- CZ : An annual number series for SPC applications is applied. Example: SPC/CZYZZZZ/1.
- DE : A certain range of numbers within the series of patent application numbers is used for SPC applications.
- DK : CA YYYY XXXXXX.
- EE : C YYYY NNNN (where C denotes the SPC; YYYY the year and NNN the number of the SPC application of the year).
- ES : CYYYYNNNNN.
- FI : Annual number series in format: L CCYY NNNN, e.g. L 2000 0001.
- FR : AACXXXX (where AA is the year of filing of the application, C is for an SPC (type of title) and XXXX the registration number). Example: 97C0019 means the 19th SPC filed in 1997; no distinction is made between a medicinal and a phytopharmaceutical product.
- GB : SPCs are identified SPC/GB/, followed by the two-digit year and the case number. The case numbers are ordered chronologically by the application date, beginning with 001 for the first application of the calendar year, e.g. SPC/GB/99/001 was the first application received in 1999; no distinction is made between medicinal and phytopharmaceutical products.
- IE : The Office uses the format SPC YYYYYNNN, where YYYYY represents the year in which the application is filed and NNN is the application number, commencing with 001 for the first application filed in a given year.
- IT : The Office uses the following format for SPC application numbers: UBYYCCPN. The first two digits are the abbreviation of "Ufficio Brevetti," the next two (YY) denote the filing year of the SPC application, the letters CCP the type of industrial property title, and N the serial number of the SPC application in ascending order, starting with 1.
- JP : The Office uses an annual numbering series for SPC applications consisting of a numeral to identify the year of filing (by year of the reign of the Emperor until 1999) followed by a six digit number starting with 700 001.
- KR : No specific numbering system is applied. The application number of patent is used.
- LU : Upwards series; as SPCs are entered in the Patent Register, the numbering system for patents is used.
- MD : C YYYY NNNN.
- NL :
 - From 1993 to 1999, the number system was YY0NNN, where YY are the last two digits of the year of filing, 0 is the numeral zero and NNN is a serial number from 001 onwards.
 - Since 2000, a serial numbering system beginning with 300 001.
- NO : SPC/NO YYYYY NNN, where YYYYY is the year and NNN is a three digit number (e.g. SPC/NO 2000 001).



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.26

- SE : A special number is given to an SPC consisting of seven digits and a check digit. The first two digits indicate the last two digits of the year, the digit 9 indicates the SPC, and the four digits indicate a serial number. For example, 0090004-3 is the fourth SPC application in the year 2000, and 3 is the check digit.
- US : Publication number of patent is used.

(ii) Concerning the numbering system for registrations or grants of SPCs (if different from (a)(i))

- BE : The application number is used.
- CH : The Office uses the basic patent number with an addition ("CNNNNNN").
- CY : It is planned as follows: CY/year/001.
- DE : The number of the granted SPC is identical to the number of the application for an SPC.
- DK : CR YYYY XXXXXX.
- FI : Serial number in grant order.
- GB : There is no change to the application number to signify that the application has been granted.
- IE : The granted SPC retains the application number given.
- IT : The number of the granted SPC is identical to the number of the application for an SPC.
- JP : No specific number is given. The granted SPC takes the patent number.
- MD : The number of the granted SPC is identical to the number of the applications for an SPC.

(b) In the field of phytopharmaceutical products

(i) Concerning the numbering system for applications for SPCs

- AT : The application number and the registration number are prefixed with "SZ" followed by a serial number, which restart at 1 every year and the four digit number of the year (SZ NNNN/YYYY).
- AU : No specific numbering system is applied (see replies to Questions 7 and 9).
- BE : Before 2000: 09Y C XXXX, since 2000: 2xxxC/XXX.
- CH : The Office uses the basic patent number with an addition ("CNNNNNN").
- CZ : An annual number series for SPC applications is applied. Example: SPC/CZYYYYY/1.
- DE : The same numbering system as for SPCs for medicinal products is used.
- DK : CA YYYY XXXXXX.
- EE : C YYYY NNNN (where C denotes the SPC, YYYY the year and NNN the number of the SPC application of the year).
- ES : CYYYYNNNNN.
- FI : Annual number series in format K CCYY NNNN, e.g. K 1998 0004.
- FR : AACXXXX (where AA is the year of filing of the application, C is for an SPC (type of title) and XXXX the registration number). Example: 97C0019 means the 19th SPC filed 1997; no distinction is made between a medicinal and a phytopharmaceutical product.
- GB : SPC's are identified SPC/GB, followed by the two digit year and the case number. The case numbers are ordered chronologically by the application date beginning with 001 for the first application of the calendar year, e.g., SPC/GB 99/001 was the first application received in 1999; no distinction is made between medicinal and phytopharmaceutical products.
- IE : The Office uses the format SPC YYYYYNNN, where YYYYY represents the year in which the application is filed and NNN is the application number, commencing with 001 for the first application filed in a given year.
- IT : See answer given to question 12(a)(i).
- JP : The Office uses an annual numbering series for SPC applications consisting of a numeral to identify the year of filing (by year of the reign of the Emperor until 1999) followed by a six-digit number starting with 700 001.
- KR : No specific numbering system is applied. The application number of patent is used.
- MD : C YYYY NNNN.
- NL :
 - From 1997 to 1999, the number system was YY1NNN, where YY are the last two digits of the year of filing, 1 is the numeral one and NNN is a serial number from 001 onwards.
 - Since 2000, a serial numbering system beginning with 350 001.
- NO : SPC/NO YYYYY NNN, where YYYYY is the year and NNN is a three-digit number (e.g. SPC/NO 2000 001).



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.27

SE : A special number is given to an SPC consisting of seven digits and a check digit. The first two digits indicate the last two digits of the year, the digit 9 indicates the SPC, and the four digits indicate a serial number. For example, 0090004-3 is the fourth SPC application in the year 2000, and 3 is the check digit.

US : Publication number of patent is used.

(ii) Concerning the numbering system for registrations or grants of SPCs (if different from (b)(i))

BE : The application number is used.

CH : The Office uses the basic patent number with an addition ("CNNNNNN").

CY : It is planned as follows: CY/Year/001.

DE : The number of the granted SPC is identical to the number of the application for a SPC.

DK : CR YYYY XXXXXX.

FI : Serial number in grant order.

GB : There is no change to the application number to signify that the application has been granted.

IE : The granted SPC retains the application number given.

IT : See answer given to Question 12(a)(ii).

MD : The number of the granted SPC is identical to the number of the application for an SPC.

Remarks:

EE : The numbering of SPC grants will be different from that of SPC applications (no SPC has been granted so far).

IE : See Appendix 12.

JP : No specific number is given. The granted SPC takes the patent number.

[Summary follows]



SUMMARY

1. With regard to the grant of SPCs, in the field of medicinal products as well as phytopharmaceutical products, the replies show that:

- 24 Offices (AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, SE, US) grant SPCs in the field of medicinal products and in the field of phytopharmaceutical products, whereas two Offices (UA, SI) provide, in a particular manner, protection derived from some general national legislation;
- 32 offices (AP, BG, BY, CL, CN, CU, EA, EP, HU, JO, KZ, LT, MA, MC, MK, MX, MY, NZ, OA, OM, PA, PL, PT, QA, RO, RU, SI, SK, TM, TR, UA, VE) do not yet grant SPCs, although six of them (BG, HU, KZ, LT, SI, SK) intend to grant SPCs in the field of medicinal products and in the field of phytopharmaceutical products;
- 18 Offices (AP, BY, CA, CL, CN, CU, EP, MC, MK, MX, MY, NZ, OM, PA, PL, QA, RO, VE) do not intend, at least in the near future, to grant SPCs in the field of medicinal products and 15 of those (AP, CL, CN, CU, MC, MK, MX, MY, NZ, OM, PA, PL, QA, RO, VE), in the field of phytopharmaceutical products.

2. As to the publication of applications for SPCs,

- 25 Offices (AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE), in the field of medicinal products, and 24 Offices (AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, RO, SE), in the field of phytopharmaceutical products, publish or intend to publish in their Official Gazettes, whereas
- seven Offices (AP, CN, KZ, MX, MY, OA, US) do not intend to do so either for medicinal or for phytopharmaceutical products.

3. As regards the grant of SPCs,

- 26 Offices (AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, LV, MD, NL, NO, PT, RO, SE, US) publish or intend to publish grants in their Official Gazettes.

4. Several Offices enter bibliographic data of the documents relating to SPCs in internal or commercial databases (see replies to Question 11).

5. 22 Offices (AT, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, IE, IT, JP, KR, LU, MD, NL, NO, SE, US) gave information on the numbering system that they used for SPC applications or grants in the field of medicinal products and phytopharmaceutical products. The following formats (or examples) were given by the Offices:

- (i) for applications for SPCs,
 - SZ NNNN/YYYY (used by AT for applications and grants);
 - before 2000: YYCNNNN; since 2000: YYYYC/NNN (used by BE for applications and grants)⁽¹⁾;
 - CNNNNNN (used by CH for applications and grants);
 - SPC/CZYYYYY/1 (used by CZ);
 - CA CCYY XXXXXX (used by DK);
 - C YYYY NNNN (used by EE)⁽¹⁾;
 - C YYYY NNNNN (used by ES);
 - L YYYY NNNN (used by FI for medicinal products)
K YYYY NNNN (used by FI for phytopharmaceutical products);
 - YYCNNNN (used by FR for applications and grants)⁽¹⁾;
 - SPC/GBYY/NNN (used by GB for applications and grants);
 - SPC YYYYNNN (used by IE for applications and grants);



- UBYYCCPN (used by IT for applications and grants);
 - YYYY – 700 001 (used by JP)⁽²⁾;
 - (Year of the reign of the Emperor) – 700 001 (used by JP until 1999)⁽²⁾;
 - C YYYY NNNN (used by MD for applications and grants);
 - 300 001 (used by NL for applications and grants of medicinal products since 2000)⁽²⁾
350 001 (used by NL for applications and grants of phytopharmaceutical products since 2000)⁽²⁾
YY0NNN (used by NL for applications and grants of medicinal products from 1993 to 1999)⁽²⁾
YY1NNN (used by NL for applications and grants of phytopharmaceutical products from 1997 to 1999)⁽²⁾;
 - SPC/NO YYYY NNN (used by NO for applications and grants);
 - YY9NNNN-D (used by SE for applications and grants)⁽²⁾;
- (ii) for registrations or grants of SPCs,
- CY/YYYY/NNN (planned by CY);
 - CR CCYY NNNNN (used by DK).

6. Examples of announcements concerning SPC applications and SPC grants published by several Offices (AT, AU, BE, CH, CZ, DE, DK, EE, ES, FR, GB, IE, IT, JP, LU, LV, NL, NO, PT, SE, US) are reproduced as Appendices 1 to 21 to this Survey.

[Appendices follow]

⁽¹⁾ Note regarding the format used by BE, EE and FR. The letter “C” contained in the number series denotes the kind of industrial property right, namely, the SPC (CCP in French)

⁽²⁾ See reply to question 12



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

APPENDIX 1

AT

AT
Österreichisches
Patentblatt
92. Jg./Nr. 11
November 1995
FG4A/FG4B Erteilungen - FG4A/FG4B Erteilungen auf dem Gebiet des
Umweltschutzes bzw. Energiesparens - SC4A/SC4B Ausgegebene
Patentschriften - Schutzzertifikate
Seite 2958

Table with columns for patent numbers, dates, and descriptions. Includes entries for F24H 1/50, F24H 9/02, F24H 9/12, F24H 9/20, F24J 2/04, G01B 21/02, G02B 21/02, G02B 13/14, G02C 5/22, G05D 16/06, F18K 31/126, G10D 1/02, H01F 29/04, H02B 1/06, H02H 3/08, H04M 1/15, H05K 5/02, B01D (U), D01F (E), AUSGEGEBENE PATENTSCHRIFTEN, SCHUTZZERTIFIKATE, A) EINGEREICHTE ANMELDUNGEN: C07D 513/04.



APPENDIX 2

AU

AUSTRALIAN OFFICIAL JOURNAL OF PATENTS

23 December 1999

Alteration of Name in Register – cont'd

676810 **ABB K.K.** The name of the patentee(s) has been changed to **ABB Alstrom Power K.K.**

694008 **Courtaulds Aerospace, Inc.** The name of the patentee(s) has been changed to **PRC-DeSoto International, Inc.**

694281 **The Cronos Group Societe Anonyme** The name of the patentee(s) has been changed to **The Cronos Group S.A.**

694376 **Courtaulds Aerospace, Inc.** The name of the patentee(s) has been changed to **PRC-DeSoto International, Inc.**

696472 **Bretts Limited** The name of the patentee(s) has been changed to **Bretts Pty Limited**

Extensions of Term of Standard Patents, Section 70**Application filed**

The following application(s) for Extension of Term under Section 70 have been filed.

644939 **Merck Sharp & Dohme Ltd.**

MAXALT (rizatripan benzoate)

Grant

The following application(s) for Extension of Term have been granted under Section 74.

539618 **Dr. Karl Thomae G.m.b.H.**

PERSANTIN SR (Dipyridamole)

Date extended term due to expire on 12/01/2006

540621 **Pharmacia & Upjohn S.p.A.**

DOSTINEX Cabergoline

Date extended term due to expire on 31/03/2006

560160 **Schering A.G.**

ADVANTAN

Date extended term due to expire on 16/08/2007

563962 **Chiron Corp.**

BETAFERON

Date extended term due to expire on 12/10/2008

565613 **Novartis AG**

Dihydroergotamine mesylate nasal spray

Date extended term due to expire on 28/01/2008

Extensions of Term, Standard Patent – cont'd

566881 **Glaxo Group Ltd.**

ZINNAT (Cefuroxime) as axetil (amorphous)

Date extended term due to expire on 21/07/2007

578703 **BYK Gulden Lomberg Chemische Fabrik GmbH**

SOMAC (pantoprazole)

Date extended term due to expire on 23/01/2010

591066 **Novartis AG and Henkel Kommanditgesellschaft Auf Aktien**

disodium pamidronate in crystalline pentahydrate form

Date extended term due to expire on 05/08/2010

594082 **Glaxo Group Ltd.**

ZINNAT (Cefuroxime as axetil)

Date extended term due to expire on 21/07/2007

595192 **Galderma Research & Development**

Differin Topical Gel adapalene

Date extended term due to expire on 29/11/2010

599988 **Pharmacia & Upjohn AB**

Estring (estradiol/oestradiol) Vaginal Ring

Date extended term due to expire on 25/10/2011

627456 **Schering Aktiengesellschaft**

LEVOVIST

Date extended term due to expire on 04/07/2011

630251 **Boehringer Ingelheim Pharmaceuticals Inc. and Dr Karl Thomae GmbH**

Nevirapine ("Viramune")

Date extended term due to expire on 07/05/2012

635401 **Novartis AG and University College London**

SIMULECT basiliximab

Date extended term due to expire on 18/02/2014

636330 **Glaxo Wellcome Inc.**



Appendix 2, page 2

AU

AUSTRALIAN OFFICIAL JOURNAL OF PATENTS

13 January 2000

Opposition under Section 104(4) - Withdrawn

635514 Monsanto Company (Zeneca Limited)

Application Withdrawn

694510 ANI Corporation Limited, The (BHP Steel (RP) Pty Ltd)

Letters Patent Sealed**Petty Patents**

The following Petty Patent Specification(s) were sealed and notified as open to public inspection on the date shown above the numbers.

Notices under the provision of Section 28(1) \S 68B(3) may be lodged at the Patent Office within the prescribed time.

13 Jan 2000

52695/99	714830	35091/99	714859
18375/99	714940	23845/99	714941
53623/99	715006	33978/99	715009
58347/99	715045	47401/99	715102
17368/99	715106		

Offer To Surrender Petty Patent

It is hereby notified that **Buono-Net Australia Pty Limited, Unit 3 10 Richmond Road., Homebush, NSW 2140 Australia**, the Patentee of Petty Patent 686988 dated 12 February 1998 for an invention titled 'Body washer and exfoliator' offers to surrender the said Petty Patent Any person desiring to be heard before the said offer of surrender is accepted must lodge a request to be heard within one month from the date of this journal

It is hereby notified that **Firebelt Pty Limited, 10-12 Pacific Highway, Chinderah, NSW 2487, Australia**, the Patentee of Petty Patent 667454 dated 21 March 1996 for an invention titled 'A vehicle refuse bin combination' offers to surrender the said Petty Patent Any person desiring to be heard before the said offer of surrender is accepted must lodge a request to be heard within one month from the date of this journal

Proceedings Under Section 215**Amendment under Section 215, death of the applicant**

Application 65779/98

The Applicant, Gerry S. Linseth has deceased. Irene A. Linseth, personal representative of the estate has been recorded as the applicant.

Assignments Registered

679265 Paul Semrani The patent has been assigned to New Dimensions (Aust) Pty Ltd

Extensions of Term of Standard Patents, Section 70**Application accepted**

Notice of opposition under Section 75(1) to the undermentioned application(s) for an extension of term may be lodged at the Patent Office within the prescribed time.

644939 Merck Sharp & Dohme Ltd.

MAXALT (rizatripan benzoate)

Address for Service: SPRUSON & FERGUSON GPO Box 3898 SYDNEY NSW 2001

Date extended term due to expire on 08/06/2014

Grant

The following application(s) for Extension of Term have been granted under Section 74.

526270 Akzo Nobel N.V.

Vecuronium Bromide (C34H57BrN2O4)

Date extended term due to expire on 26/02/2001

529263 Daiichi Pharmaceutical Co., Ltd

Ofloxacin (C18H20FN3O4)

Date extended term due to expire on 02/09/2006

529315 Merck and Co. Inc.

PRIMAXIN (imipenem + cilastatin sodium)

Date extended term due to expire on 23/02/2002

529565 Schering A.G.

Ultravist

Date extended term due to expire on 07/03/2005

530380 Merck and Co. Inc.

RENITEC (enalaprilmaleate)

Date extended term due to expire on 16/04/2001

538130 Janssen Pharmaceutica N.V.

LIVOSTIN Levocabastine

Date extended term due to expire on 16/01/2006

548996 Merck and Co., Inc.

ZOCOR (simvastatin)

Date extended term due to expire on 19/07/2005

553845 Janssen Pharmaceutica N.V.



APPENDIX 3

BE

LISTES CUMULATIVES -- CUMULATIEVE LIJSTEN	
CERTIFICATS COMPLEMENTAIRES DE PROTECTION DES MEDICAMENTS	
AANVUL. BESCHERMINGSCERTIFICATEN VOOR DE GENEESMIDDELEN	
LISTE DES DEMANDES	
LIJST VAN DE AANVRAGEN	

NUMERO DE LA DEMANDE	: 2001C/001
DATE DE LA DEMANDE	: 02/01/01
TITULAIRE	: MERCK & CO. INC. 126 East Lincoln Avenue P.O. Box 2000, RAHWAY, NEW JERSEY 07065-0900
AMM BELGE	
NUMERO	: EU/1/99/111/001
DATE DE DELIVRANCE	: 04/06/1999
PRODUIT	: EPAVIRENZ.
AMM CEE	
NUMERO	:
DATE DE DELIVRANCE	: / /
PAYS	:
BREVET DE BASE	: EUROPEEN
NUMERO DE PUBLICATION	: 10582455
TITRE	: BENZOXAZINONES UTILISEES COMME INHIBITEURS DE TRANSCRIPTASE INVERSE DE HIV

NUMERO DE LA DEMANDE	: 2001C/002
DATE DE LA DEMANDE	: 02/01/01
TITULAIRE	: PRE JAY HOLDINGS LTD; WOCO INVESTMENTS LTD 9282 Elviage Drive, LONDON, ONTARIO N6K 4N5, 17 Metamora Crescent, LONDON, ONTARIO N6G 1R2 (CA)
AMM BELGE	
NUMERO	: 0410IS0231F003
DATE DE DELIVRANCE	: 03/07/2000
PRODUIT	: ESTRADIOLUM / DYDROGESTERONUM
AMM CEE	
NUMERO	: 46050.00.00
DATE DE DELIVRANCE	: 27/08/1999
PAYS	: REPUBLIQUE FEDERALE D'ALLEMAGNE
BREVET DE BASE	: EUROPEEN
NUMERO DE PUBLICATION	: 10136011
TITRE	: METHODE DE TRAITEMENT HORMONAL DE TROUBLES DE LA PERIMENOPAUSE, MENOPAUSE ET POSTMENOPAUSE ET EMBALLAGE A PREPARATIONS MULTIPLES DANS CE BUT.

NUMERO DE LA DEMANDE	: 2001C/003
DATE DE LA DEMANDE	: 04/01/01
TITULAIRE	: FRESENIUS A.G. Gluckensteinweg 5, D-61350 BAD HOMBURG
AMM BELGE	
NUMERO	: 1250 IS 114 F12
DATE DE DELIVRANCE	: 17/07/2000
PRODUIT	: POLY (0-2-HYDROXYETHYL)AMYLUM (degré de substitution = 0,38-0,45 ; poids moléculaire moyen = 130.000)
AMM CEE	
NUMERO	: 420930000
DATE DE DELIVRANCE	: 22/06/1999
PAYS	: REPUBLIQUE FEDERALE D'ALLEMAGNE
BREVET DE BASE	: EUROPEEN
NUMERO DE PUBLICATION	: 10402724
TITRE	: HYDROXYETHYLAMIDON COMME DILUANT DU PLASMA ET SON PROCEDE DE PREPARATION.

NUMERO DE LA DEMANDE	: 2001C/004
DATE DE LA DEMANDE	: 10/01/01
TITULAIRE	: BEECHAM GROUP P.L.C. Four New Horizons Court Harlequin Avenue, Brentford Middlesex TW8 9EP
AMM BELGE	
NUMERO	: EU/1/00/137/001
DATE DE DELIVRANCE	: 17/07/2000
PRODUIT	: ROSIGLITAZONE.
AMM CEE	
NUMERO	:
DATE DE DELIVRANCE	: / /
PAYS	:
BREVET DE BASE	: EUROPEEN
NUMERO DE PUBLICATION	: 10306228
TITRE	: THIAZOLIDINEDIONES SUBSTITUEES

NUMERO DE LA DEMANDE	: 2001C/005
DATE DE LA DEMANDE	: 11/01/01

2001	



BE

LISTES CUMULATIVES -- CUMULATIEVE LIJSTEN	
CERTIFICATS COMPLEMENTAIRES DE PROTECTION DES MEDICAMENTS	
AANVUL. BESCHERMINGSCERTIFICATEN VOOR DE GENEESMIDDELEN	
LISTE DES DELIVRANCES 2001	
LIJST VAN DE VERLENINGEN	
NUMERO DU CERTIFICAT	: 099C0039
DATE DE LA DELIVRANCE	: 06/02/01
TITULAIRE	: GENETICS INSTITUTE INC. 87 Cambridgepark Drive, Cambridge, MASSACHUSETTS 02140
AMM BELGE	
NUMERO	: EU/1/99/103/001
DATE DE DELIVRANCE	: 13/04/1999
PRODUIT	: MOROCTOCOG ALFA
AMM CEE	
NUMERO	: / /
DATE DE DELIVRANCE	: / /
PAYS	
BREVET DE BASE	: EUROPEEN
NUMERO DE PUBLICATION	: 10218712
TITRE	: NOUVELLES PROTEINES PROCOAGULANTES.
DATE DE DEBUT	: 11/04/2006
DATE DE FIN	: 11/04/2011
DUREE	: 1826 JOURS
NUMERO DU CERTIFICAT	: 099C0040
DATE DE LA DELIVRANCE	: 06/02/01
TITULAIRE	: PHARMACIA & UPJOHN A.B. S-112 87 STOCKHOLM
AMM BELGE	
NUMERO	: EU/1/99/103/001
DATE DE DELIVRANCE	: 13/04/1999
PRODUIT	: MOROCTOCOG ALFA
AMM CEE	
NUMERO	: / /
DATE DE DELIVRANCE	: / /
PAYS	
BREVET DE BASE	: EUROPEEN
NUMERO DE PUBLICATION	: 10506757
TITRE	: DERIVE DU FACTEUR HUMAIN VIII DE RECOMBINAISON
DATE DE DEBUT	: 06/12/2010
DATE DE FIN	: 13/04/2014
DUREE	: 1224 JOURS
NUMERO DU CERTIFICAT	: 2000C/011
DATE DE LA DELIVRANCE	: 06/03/01
TITULAIRE	: PHARMACIA & UPJOHN S.P.A. Via Robert Koch 1.2, I-20152 MILAN
AMM BELGE	
NUMERO	: 277 IS 327 F3
DATE DE DELIVRANCE	: 13/01/2000
PRODUIT	: EXEMESTANUM.
AMM CEE	
NUMERO	: PL 00032/0236
DATE DE DELIVRANCE	: 16/12/1998
PAYS	: ROYAUME-UNI
BREVET DE BASE	: BELGE
NUMERO DE PUBLICATION	: 05905067
TITRE	: ANDROSTA-1,4-DIENE-3,17-DIONES SUBSTITUEES, LEUR PROCEDE DE FABRICATION ET MEDICAMENTS LES CONTENANT.
DATE DE DEBUT	: 08/07/2006
DATE DE FIN	: 08/07/2011
DUREE	: 1826 JOURS
NUMERO DU CERTIFICAT	: 2000C/012
DATE DE LA DELIVRANCE	: 06/03/01
TITULAIRE	: AKZO NOBEL N.V. Velperweg 76, NL-6824 BM ARNHEM
AMM BELGE	
NUMERO	: 3009 IE 59 F3
DATE DE DELIVRANCE	: 14/02/2000
PRODUIT	: DESOGESTREL / ETHINYLESTRADIOL 10/7 ; DESOGESTREL / ETHINYLESTRADIOL 10/3 ; DESOGESTREL / ETHINYLESTRADIOL 5/1
AMM CEE	
NUMERO	: 12637
DATE DE DELIVRANCE	: 15/03/1995
PAYS	: SUEDE



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.37

Appendix 3, page 4

BE

LISTES CUMULATIVES -- CUMULATIEVE LIJSTEN
CERTIFICATS COMPL. DE PROTECTION DES PRODUITS PHYTOPHARMACEUTIQUES
AANVUL. BESCHERMINGSCERT. VOOR DE GEWASBESCHERMINGSMIDDELEN

LISTE DES DELIVRANCES *2001*
LIJST VAN DE VERLENINGEN

NUMERO DU CERTIFICAT : 2001C/008
DATE DE LA DELIVRANCE : 05/06/01
TITULAIRE : ISHIHARA SANGYO KAISHA LTD
3-15, Edobori, 1-chome, Nishi-ku, OSAKA 550-0002

ANN BELGE
NUMERO : 9209/B
DATE DE DELIVRANCE : 28/09/2000
PRODUIT : FOSTHIAZATE.

ANN CEE
NUMERO : 0522
DATE DE DELIVRANCE : 26/02/1998
PAYS : ROYAUME-UNI

BREVET DE BASE : EUROPEEN
NUMERO DE PUBLICATION : 10146748
TITRE : COMPOSE ORGANOPHOSPHORE, PROCEDE POUR LE
PREPARER ET COMPOSITION INSECTICIDE, MITICIDE
OU NEMATOCIDE LE CONTENANT.

DATE DE DEBUT : 07/11/2004
DATE DE FIN : 07/11/2009
DUREE : 1826 JOURS

[Appendix 4 follows]



APPENDIX 4

CH



SCHWEIZERISCHE EIDGENOSSENSCHAFT - CONFÉDÉRATION SUISSE - CONFEDERAZIONE SVIZZERA

BESCHEINIGUNG

Ober die Erteilung eines ergänzenden Schutzzertifikates für einen Wirkstoff oder eine Wirkstoffzusammensetzung mit der Nr.

CERTIFICAT

de la délivrance d'un certificat complémentaire de protection pour un principe actif ou une composition de principes actifs no

CERTIFICATO

del rilascio di un certificato protettivo complementare per un principio attivo o composizione di principi attivi no.

C622529/01

Inhaber/in
Titulaire
Titolare

Pharmacie Spa
Via Robert Koch 1.2
Milano (IT)

Bezeichnung des Erzeugnisses
Désignation du produit
Designazione del prodotto

Idarubicin

Datum und Nr. der Zulassung
Date et no. de l'autorisation
Data e no. dell'autorizzazione

30.03.1992; IKS-Nr. 50 838

Nr. des Grundpatentes
No. du brevet de base
No. del brevetto di base

622 529

Beginn der Laufzeit
Début de la protection
Inizio della protezione

16.06.1996

Ablaufdatum
Date de l'échéance
Data della scadenza

15.06.2001

Die Eintragung des ergänzenden Schutzzertifikates erfolgt ohne Gewährleistung des Staates.

Le certificat complémentaire de protection est enregistré sans garantie de l'Etat

Il certificato protettivo complementare è registrato senza garanzia dello Stato.

30.04.1996

716 DFI 9601

Eidgenössisches Institut für
Geistiges Eigentum
Institut Fédéral de la Propriété
Intellectuelle
Istituto Federale della Proprietà
Intellettuale



Appendix 4, page 2

CH

CH PMMBI/FBDM/FBDM 8

30.4.96

10.2.

Zurückziehungen/
Zurückweisungen von bekannt-
gemachten Patentgesuchen

Retraits/rejets de demandes
de certificat publiées

Ritiri/rigetti di domande
di certificato pubblicate

- ① 574 930
- ② 30.10.1995
- ⑦ Otsuka Pharmaceutical Company, Limited
9, Kanda-Tsukasa-cho, 2-chome
Chiyoda-ku, Tokyo (JP)
- ⑩ Micheli & Cie., 1226 Thônex Geneve
- ④ Procédé pour la préparation de
dérivés du 3,4-dihydrocarbostyril.
- ② OICM-no 46 117 / 28.06.1984
- ③ Carteolol Hydrochloride
La demande a été retirée.

10.11. FG3X

Erteilte Zertifikate

Certificats délivrés

Certificati rilasciati

10.11.1.
Zu nationalen Patenten
Se référant à des brevets nationaux
Referendosi a brevetti nazionali

- ① C582161/01
- ② 19.10.1995
- ⑦ Pharmacia Spa
Via Robert Koch 1.2
Milano (IT)
- ⑩ Bovard AG, 3000 Bern 25
- ④ 582 161
- ④ Verfahren zur Herstellung von
Pyrazin-4-oxydderivaten.
- ② IKS-Nr. 47 644 / 20.06.1986
- ③ Acipimox
- ④ 26.04.1998

- ① C585166/01
- ② 26.10.1995
- ⑦ F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4002 Basel
- ④ 585 166
- ④ Verfahren zur Herstellung von
Polyenverbindungen.
- ② IKS-Nr. 49 227 / 19.03.1990
- ③ Acitretin
- ④ 29.03.1998

- ① C589059/01
- ② 24.10.1995
- ⑦ Schering-Plough Ltd.
Toepferstrasse 5
6004 Luzern
- ⑩ Hug Interlizenz, 8035 Zürich
- ④ 589 059
- ④ Verfahren zur Herstellung des
N-Methyl-D-glucaminsalzes von
2-(2'-Methyl-3'-trifluormethylanilin)-
nicotinsäure.
- ② IKS-Nr. 43 985 / 10.08.1982
- ③ Flunixin Meglumine
- ④ 10.08.1997

- ① C593287/01
- ② 17.10.1995
- ⑦ SANOFI
32-34, rue Marbeuf
Paris (FR)
- ⑩ A. Braun, Braun, Héritier,
Eschmann AG, 4003 Basel
- ④ 593 287
- ④ Procédé de préparation de dérivés
de pyridinium.
- ② OICM-no 49 068 / 24.11.1992
- ③ Ticlopidine
- ④ 14.01.1999

- ① C601290/01
- ② 27.10.1995
- ⑦ Synthelabo
22, Avenue Galilée
Le Plessis-Robinson (FR)
- ⑩ Bovard AG, 3000 Bern 25
- ④ 601 290
- ④ Procédé de préparation
d'un nouveau dérivé du
4,5-Azimido-benzamide.
- ② OICM-no 47 711 / 18.11.1986
- ③ Alizapridum

④ 09.03.2000

- ① C603669/01
- ② 24.10.1995
- ⑦ Eli Lilly and Company
307 East McCarty Street
Indianapolis/IN (US)
- ⑩ E. Blum & Co., 8044 Zürich
- ④ 603 669
- ④ Verfahren zur Herstellung von
kondensierte heterocyclische Ringe
aufweisenden Verbindungen und
deren Verwendung.
- ② IKS-Nr. 42 863 / 16.03.1982
- ③ Vindesin
- ④ 16.03.1997

- ① C608500/01
- ② 26.10.1995
- ⑦ F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4002 Basel
- ④ 608 500
- ④ Verfahren zur Herstellung von
Thiazinderivaten.
- ② IKS-Nr. 46 929 / 20.02.1986
- ③ Tenoxicam
- ④ 25.08.1999

- ① C609675/01
- ② 09.10.1995
- ⑦ Eli Lilly and Company
307 East McCarty Street
Indianapolis/IN (US)
- ⑩ E. Blum & Co., 8044 Zürich
- ④ 609 675
- ④ Verfahren zur Herstellung von
3-Aryloxy-3-phenylalkylaminen.
- ② IKS-Nr. 46 347 / 26.03.1991
- ③ Fluoxetin
- ④ 06.01.2000

- ① C612947/01
- ② 12.10.1995
- ⑦ Pharmacia Spa
Via Robert Koch 1.2
Milano (IT)
- ⑩ Bovard AG, 3000 Bern 25
- ④ 612 947
- ④ Verfahren zur Herstellung von
Adriamycinen.
- ② IKS-Nr. 45 206 / 17.05.1983
- ③ Epirubicin
- ④ 17.05.1998

- ① C613443/01
- ② 26.10.1995
- ⑦ G.D. Searle & Co.
Chicago/IL (US)
- ⑩ E. Blum & Co., 8044 Zürich
- ④ 613 443
- ④ Verfahren zur Herstellung von
16-oxydierten Prostanoidderivaten
und deren Verwendung
- ② IKS-Nr. 46 945 / 21.06.1985
- ③ Misoprostol
- ④ 25.03.2000

- ① C622529/01
- ② 18.10.1995
- ⑦ Pharmacia Spa
Via Robert Koch 1.2
Milano (IT)
- ⑩ Bovard AG, 3000 Bern 25
- ④ 622 529
- ④ Verfahren zur Herstellung von
Anthracyclinglicosiden und optisch
aktiven Anthracyclononen.
- ② IKS-Nr. 50 838 / 30.03.1992
- ③ Idarubicin
- ④ 15.06.2001

[Appendix 5 follows]



APPENDIX 5

CZ

ČESKÁ REPUBLIKA
ÚŘAD PRŮMYSLOVÉHO VLASTNICTVÍ

**DODATKOVÉ OCHRANNÉ OSVĚDČENÍ
K PATENTU Č.**

Číslo osvědčení:
Majitel osvědčení:
Název přípravku:
Číslo první registrace:
Datum první registrace:
Rozhodnutí o registraci vydal:
Platnost osvědčení do:

V Praze dne

Za předsedu:

[Appendix 6 follows]



APPENDIX 6

DE

Beim Deutschen Patentamt sind die nachfolgend genannten Zertifikatsanmeldungen für Arzneimittel eingegangen. Die Veröffentlichung erfolgt gemäß Verordnung (EWG) Nr. 1768/92 des Rates vom 18. Juni 1992 (Artikel 9 Abs. 2).

Sie enthält folgende Angaben:

Bezeichnung der Erfindung

Name und Anschrift des Anmelders

Nummer(n) und Zeitpunkt der Genehmigung des Bundesgesundheitsamts (BGA) bzw. des Instituts für Arzneimittelwesen der ehemaligen DDR (IfA)

Bezeichnung des Erzeugnisses

Gegebenenfalls Land, Nummer und Zeitpunkt der ersten Genehmigung für das Inverkehrbringen in der Gemeinschaft (EG).

Zertifikatsanmeldungen:

A61K 7/48 P 31 84 409 0
Verfahren und Mittel zur Behandlung der Haut
Scotts Pharmaceuticals Ltd., Woodbridge Meadows, Guildford, Surrey, GB
BGA: 26760.00.00 vom 20.10.92
Efalith
EG: Großbritannien, 4382/0009 vom 27.06.90

A61K 9/50 P 31 75 230.6
Mikroverkapselung wasserlöslicher Polypeptide
Syntex (U.S.A.) Inc., 3401 Hillview Avenue, Palo Alto, California 94303, US
BGA: 7656.00.01 vom 29.10.91
Leuprorelin (als Acetat)
EG: Frankreich, 331291.2 vom 16.08.88

A61K 31/66 P 27 28 685.7
Arzneimittel zur Bekämpfung von Virusinfektionen
Astra Läkemedel AB, Kvarnbergagatan 16, S-15185 Södertälje, SE
BGA: 15928.00.00 vom 04.05.90
Foscavir/Foscarnet
EG: Dänemark, 6705 vom 03.03.89

C07C 125/06 P 31 63 871.6
1-(Dihydroxyphenyl)-2-amino-äthanol-Derivate, Verfahren und Mittel zu ihrer Herstellung sowie diese Derivate enthaltende Mittel
Aktiebolaget Draco, Tunavägen 43, S-22101 Lund, SE
BGA: 23843.00.00, 23843.00.01, 23843.01.00, 23846.00.01, 23846.01.00, 23846.00.01 vom 31.10.91
Bombaretol (Bambee)
EG: Dänemark, 6385 vom 27.03.91

C07C 255/39 P 27 19 264.4
Substituierte Phenoxycarbonyl-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Insektizide und Akarizide sowie neue Zwischenprodukte
Bayer AG, Konzernverwaltung RP Patente Konzern, Bayerwerk, 5090 Leverkusen I, DE
BGA: 9907.00.00 vom 28.06.91
Cyfluthrin
EG: Niederlande, 10133 N vom 04.12.89

C07D 207/09 P 29 64 774.3
2,6-Dialkylbenzamide, Verfahren zu ihrer Herstellung, Zubereitungen und diese Verbindung zur Anwendung bei der Behandlung von psychischen Störungen
Astra Läkemedel AB, Kvarnbergagatan 16, S-15185 Södertälje, SE
BGA: 19325.00.00, 19325.00.01, 19325.00.02, 19325.01.02, 19329.00.00, 19329.00.01, 19329.00.02, 19329.01.02 vom 21.01.91
Remotiprid
EG: Dänemark, 8284 vom 30.03.90

C07D 207/12 P 30 65 362.4
Phenoxypropylaminderivate, Verfahren zu ihrer Herstellung, und pharmazeutische Zusammensetzungen, die sie enthalten
Teikoku Hormone Mfg. Co., Ltd., 5-1-2 chome, Akasaka, Minato-ku, Tokio, JP
BGA: 9908.01.00 vom 22.08.89
Rovit

C07D 209/42 P 32 75 293.8
Neue Derivate bicyclischer Aminosäuren, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung sowie neue bicyclische Aminosäuren als Zwischenstufen und Verfahren zu deren Herstellung

Hoechst AG
Postfach 800320, 6230 Frankfurt 80, DE
BGA: 28369.00.00, 28369.01.00 vom 03.03.93
Trandolapril
EG: Frankreich, NL 17686 vom 19.02.92

C07D 209/52 P 32 69 875.5
Derivate der cis, endo-2-Azabicyclo-(3.3.0)-octan-3-carbonsäure, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung
Hoechst AG
Postfach 800320, 6230 Frankfurt 80, DE
BGA: 15401.02.00 vom 26.09.90
Ramipril
EG: Frankreich, NL 15556 vom 10.01.89

C07D 211/58 P 32 67 923.8
N-(3-Hydroxy-4-piperidinyl)benzamid-Derivate
Janssen Pharmaceutica N.V., Turnhousebaan 30, B-2340 Beerse, BE
BGA: 13532.00.00, 13532.00.01, 13532.01.01 vom 18.01.90
Clasprid-Monohydrat
EG: Frankreich, NL 15156, NL 15155 vom 20.04.88

C07D 211/90 P 25 49 568.5
2,6-Dimethyl-3-methoxycarbonyl-4-(2'-nitrophenyl)-1,4-dihydropyridin-5-carbonsäureisobutylester, mehrere Verfahren zu seiner Herstellung sowie ihn enthaltende Arzneimittel
Bayer AG, Konzernverwaltung RP Patente Konzern, Bayerwerk, 5090 Leverkusen I, DE
BGA: 10143.00.00, 10143.01.00 vom 26.04.90
Nisoldipin
EG: Belgien, 187 IS 250 F3, 187 IS 251 F3 vom 23.08.88

[Appendix 7 follows]



APPENDIX 7

DK

Dansk Patenttidende

2000-02-21

Ansøgninger om supplerende beskyttelsescertifikat

(21) **Ans. nr.:** CA 1999 00033
(22) **Indl.dag:** 1999-12-21
(68) **Grundpatent nr.:** PR 166680
(71) **Ansøger:** Exelgyn, 6, rue Christophe Colomb, F-75008 Paris, Frankrig
(74) **Fuldmægtig:** Patentbureauet, Magnus Jensens Eftf., Frederiksborgvej 15, 3520 Farum, Danmark
(92) **DK markedsførelsesstilladelse nr.:** 30741
(92) **Dato for samme:** 1999-08-27
(95) **Produkt:** Mifepriston
(93) **Første markedsføringstilladelse i EU:** 556473.0 (FR)
(93) **Dato for samme:** 1999-08-27
(54) **Benævnelse:** Mifepriston

(21) **Ans. nr.:** CA 1999 00034
(22) **Indl.dag:** 1999-12-22
(68) **Grundpatent nr.:** 0478363
(71) **Ansøger:** MERCK & CO. INC., 126, East Lincoln Avenue, P.O. Box 2000, Rahway, New Jersey 07065-0900, USA
(74) **Fuldmægtig:** Hofman-Bang & Boutard, Lehmann & Ree A/S, Hans Bekkevoide Allé 7, 2900 Hellerup, Danmark
(92) **DK markedsførelsesstilladelse nr.:** 30290, 30291
(92) **Dato for samme:** 1999-07-12
(95) **Produkt:** Tirofibanhydrochlorid monohydrat
(93) **Første markedsføringstilladelse i EU:** 54761 (CH)
(93) **Dato for samme:** 1998-05-25
(54) **Benævnelse:** Tirofibanhydrochlorid monohydrat

(21) **Ans. nr.:** CA 1999 00035
(22) **Indl.dag:** 1999-12-23
(68) **Grundpatent nr.:** 0477295
(74) **Fuldmægtig:** Budde, Schou & Ostenfeld A/S, Vester Søgade 10, 1601 København V, Danmark
(92) **DK markedsførelsesstilladelse nr.:** K(1999) 1901
(92) **Dato for samme:** 1999-07-01
(95) **Produkt:** Eptifibatid
(93) **Første markedsføringstilladelse i EU:** K(1999) 1901
(93) **Dato for samme:** 1999-07-01
(54) **Benævnelse:** Eptifibatid

[Appendix 8 follows]



APPENDIX 8

EE




TÄIENDAVA KAITSE TUNNISTUS



TUNNISTUS ON VÄLJA ANTUD PATENDISEADUSE § 59⁷ JÄRGI.

TUNNISTUS TÕENDAB LEIUTISE REGISTREERINGUST TULENEVATE ÕIGUSTE KEHTIVUSE PIKENDAMIST TUNNISTUSES MÄRGITUD PATENDI KEHTIVUSAJA LÕPPEMISEL TUNNISTUSES NIMETATUD TOOTE SUHTES TUNNISTUSES MÄRGITUD AJANI. TÄIENDAV KAITSE KEHTIB TUNNISTUSES MÄRGITUD AJANI KUI IGA KEHTIVUSAASTA EESTI ON TASUTUD RIIGILOIV.



[Appendix 9 follows]



APPENDIX 9

ES

13. CERTIFICADOS COMPLEMENTARIOS DE PROTECCION (REGLAMENTO CEE 1768/92 Y CE 1610/96)

SOLICITUDES

- 21 C9900013
- 22 26-03-1999
- 71 Adir, S.A.R.L., 1, Rue Carle Hébert, 92415 Courbevoie Cedex. Francia.
- 39 8305723
- 54 Procedimiento de preparación de nuevos diácidos sustituidos y sus sales.
- 45 Perindopril (Bi Preterax).
- 92 62407 de 09-12-1998
- 93 NL 21997 de 05-10-1998

RESOLUCIONES

Las resoluciones que se insertan en este capítulo no son definitivas en la vía administrativa, pudiendo interponerse contra las mismas recurso de alzada en el plazo de 1 mes ante el Ilmo. Sr. Dtor. de la Oficina Española de Patentes y Marcas.

DENEGACIONES

- 21 C9900016
 - 22 09-04-1999
 - 71 Laboratorios Farmacéuticos Ravi, S.A.
 - 39 2003197
 - 54 Procedimiento para la despolimeración de la heparina para la obtención de una heparina de bajo peso molecular dotada de actividad antitrombótica.
 - 45 Hibor.
 - 92 61907/61908 16-04-1998
- Fecha denegación: 27-10-2000
- Motivos: Subsisten defectos que no han sido debidamente subsanados en el plazo previsto al efecto según lo establecido en el artículo 10.4 del Reglamento (CEE) N° 1768/92.



Appendix 9, page 2

ES

16 MAYO 2000 – BOLETIN OFICIAL DE LA PROPIEDAD INDUSTRIAL

5023

SOLICITUDES

<p><u>22</u> C9800032</p> <p><u>23</u> 27.10.1998</p> <p><u>73</u> Glaxo Group Limited. Berkeley Avenue, Greenford. Middlesex UB6 0NN, Gran Bretaña.</p> <p><u>68</u> ES 2058292</p> <p><u>54</u> Derivados de indol.</p> <p><u>92</u> 61828 de 31.07.1998</p> <p><u>93</u> SE 13382 de 10-03-1998</p>	<p><u>21</u> C9800013</p> <p><u>22</u> 14-04-1998</p> <p><u>73</u> Hafslund Nycomed Ph, 25 St. Peter Strasse. 4021 Linz. AT.</p> <p><u>68</u> 473074</p> <p><u>54</u> Un procedimiento para preparación de derivados de tienotiacina.</p> <p><u>95</u> Lornoxicam.</p> <p><u>92</u> 61836 de 14-10-1997</p> <p><u>93</u> DK15784 de 27-11-1995</p> <p><u>94</u> 16-10-2004</p>
--	--

<p><u>22</u> C9300033</p> <p><u>23</u> 27.10.1998</p> <p><u>73</u> E.I. Du Pont de Nemours and Company. 1007 Market Street. Wilmington. Delaware 19898, Estados Unidos.</p> <p><u>68</u> ES 8706652</p> <p><u>54</u> Un procedimiento para preparar tetrazol-sustituido-benceno-sulfonamidas.</p> <p><u>92</u> 21909 de 06.05.1998</p> <p><u>93</u> IT 9181 de 27-03-1997</p>	<p><u>21</u> C9800023</p> <p><u>22</u> 01-09-1998</p> <p><u>73</u> Merck Froset Canaca Inc. 1959 Upper Water Street, P.O. Box 997, HALIFAX, Nova Scotia B3J 2X2, Canadá.</p> <p><u>68</u> 2114882</p> <p><u>54</u> Acidos hidroxialquilquinolinicos insaturados como antagonistas de leucotrienos.</p> <p><u>95</u> Montelukast sódico.</p> <p><u>92</u> 61979 de 12-03-1998</p> <p><u>93</u> FI 12766 de 25-08-1997</p> <p><u>94</u> 25-08-2012</p>
---	--

RESOLUCIONES

Las resoluciones que se insertan en este capítulo no son definitivas en la vía administrativa, pudiendo interponerse contra las mismas recurso de alzada en el plazo de 1 mes ante el Ilmo. Sr. Dtor. de la Oficina Española de Patentes y Marcas.

CONCESIONES

<p><u>21</u> C9800011</p> <p><u>22</u> 26.03.1998</p> <p><u>73</u> Zeneca Ltd., 15 Stanhope Gate, London W1Y 6LN, GB</p> <p><u>68</u> 2063253</p> <p><u>54</u> Fungicidas.</p> <p><u>95</u> Azoxistrobin</p> <p><u>92</u> 21809 de 16-01-1998</p> <p><u>93</u> DE 4248 de 04-04-1996</p> <p><u>94</u> 04-04-2011</p>	<p><u>21</u> C9800027</p> <p><u>22</u> 29-09-1998</p> <p><u>73</u> Otsuka Ph., 9 Kandatsukasa-cho, 2-chome, Chiyoda-ku, 101 Tokyo, JP</p> <p><u>39</u> 2091180</p> <p><u>54</u> Derivados del ácido 7-piperazinil o 7-morfolino 4-oxo-quinolin-3-carboxilico, su preparación y su uso como agentes antimicrobianos.</p> <p><u>95</u> Grepafloxacin.</p> <p><u>92</u> 62074 de 30.303.1998</p> <p><u>93</u> DE40682.00 de 31-07-1997</p> <p><u>94</u> 31-07-2012</p>
--	---

[Appendix 10 follows]



APPENDIX 10

FR

BOPI 93/30

195

QUATRIÈME PARTIE

PUBLICATION DES CERTIFICATS COMPLEMENTAIRES DE PROTECTION

SOMMAIRE

	Pages
A) Loi du 25 juin 1990.	
1. Liste des demandes de certificats complémentaires de protection rendues publiques	197
2. Liste des certificats complémentaires de protection délivrés	199
B) Règlement (CEE) N° 1768/92 du conseil du 18 juin 1992.	
1. Liste des demandes de certificats complémentaires de protection rendues publiques	201
2. Liste des demandes de certificats complémentaires de protection rejetées	Néant
3. Liste des certificats complémentaires de protection délivrés	Néant



FR

BOPI 93/30

201

DEMANDES DE CERTIFICATS COMPLÉMENTAIRES DE PROTECTION RENDUES PUBLIQUES

Règlement (CEE) N° 1768/92 du conseil du 18 juin 1992

Numéro national : 93C0004 déposé le 11-02-93

Demandeur : TAKEDA CHEMICAL INDUSTRIES, LTD, 1-1,
Doshomachi 4-chome, Chyo-ku OSAKA 541 (JP)

Référence du brevet de base :

N° d'enregistrement national : FR 74 32580 déposé le 27-09-74

N° de publication : 2245375 délivré le 10-07-78

Titre de l'invention : Nouveaux Amides Nonapeptides

Numéro de la 1ère A.M.M. en France : NL 15229

Date de la 1ère A.M.M. en France : 16-08-88

Produit identifié par l'A.M.M. en France : LEUPRORELIN

Numero de la 1ère autorisation dans la C.E.E. : NL 15229

Date de la 1ère autorisation dans la C.E.E. : 16-08-88

Numéro national : 93C0010 déposé le 01-04-93

Demandeur : CETUS ONCOLOGY CORPORATION, 1400
Fifty-third Street, EMERYVILLE CALIFORNIA 94608 (US)

Référence du brevet de base :

N° de dépôt européen : EP 83 306221 déposé le 13-10-83

N° de publication : 0109748 délivré le 13-04-88

Titre de l'invention : Préparations pharmaceutiques et
vétérinaires d'interleukine-2 mutée au niveau de la
cystéine-125 (mutéine), et leur production

Numéro de la 1ère A.M.M. en France : NL 15585

Date de la 1ère A.M.M. en France : 15-09-89

Produit identifié par l'A.M.M. en France : Des-alanyl-1,
sérine-125-interleukine-2

Numéro de la 1ère autorisation dans la C.E.E. : 13282

Date de la 1ère autorisation dans la C.E.E. : 03-07-89



FR

BOPI /

DEMANDES DE CERTIFICATS COMPLÉMENTAIRES DE PROTECTION REJETÉES
Reglement (CEE) N° 1768/92 du conseil du 18 juin 1992

- numéro national : 93C0008
- Demandeur : ALCATEL TRANSMISSION FAISCEAUX H
84 RUE DE LA LIBERTÉ, 38300 BOURGOIN JALLIEU
(FR)
- Numéro du brevet de base : EP 81 102 132
- Titre de l'invention : Formulation ophtalmique stabilisée
- Numéro de la 1ère A.M.M. en France : NL 13433
- Date de la 1ère A.M.M. en France : 12/05/90
- Produit identifié par l'A.M.M. en France : Trimethoprim -
Polymyxin B SULFATE
- Numéro de la 1ère autorisation dans la C.E.E. :
- Date de la 1ère autorisation dans la C.E.E. :



FR

BOPI

CERTIFICATS COMPLÉMENTAIRES DE PROTECTION DÉLIVRÉS
Règlement (CEE) N° 1768/92 du conseil du 18 juin 1992

Numéro national : 93C0008
 Date limite de validité : 15/10/98
 Titulaire : ALCATEL TRANSMISSION FAISCEAUX H
84 RUE DE LA LIBERTÉ, 38300 BOURGOIN JALLIEUX
(FR)
 Numéro du brevet de base : EP 81 102 132
 Titre de l'invention : Formulation ophtalmique stabilisée
 Numéro de la 1ère A.M.M. en France : NL 13433
 Date de la 1ère A.M.M. en France : 12/05/90
 Produit identifié par l'A.M.M. en France : Trimethoprim -
Polymyxin B SULFATE
 Numéro de la 1ère autorisation dans la C.E.E. :
 Date de la 1ère autorisation dans la C.E.E. :

[Appendix 11 follows]



APPENDIX 11

GB

10 May 2000 No. 5791



**THE PATENTS AND
DESIGNS JOURNAL**

Application Numbers:

GB 0006435.2 - GB 0007067.2

Price £12.25

Publication Numbers:

GB 2343353 - GB 2343805

Contents

i	General Information	2101	European Patents void
ii	OFFICIAL NOTICES	2101	European Patents revoked
	PROCEEDINGS UNDER THE PATENTS ACT 1977	2102	European Patents ceased
	1999 Applications for Patents filed	2104	European Patents expired
	2015 Applications terminated	2105	UK Patents ceased
	Applications published:	2106	UK Patents expired
	2017 Subject-Matter Index	2107	Other Proceedings under the Patents Act 1977 (Sections 27, 28, 30, 32, 46, 73, 75, 89A(6))
	2033 Number Index		PROCEEDINGS UNDER EC REGULATIONS 1768/92 and 1610/96
	2035 Name Index	2113	(Supplementary Protection Certificates for Medicinal Products and Plant Protection Products, respectively)
	Patents granted:		PROCEEDINGS UNDER THE REGISTERED DESIGNS ACT 1949
	2045 Number Index	2114	Certificates of Registration issued
	2058 Subject-Matter Index	2117	Designs extended
	2060 Name Index		THE BRITISH LIBRARY
	2069 European Patents granted		
	2094 Translations filed		



GB

10 May 2000 Patents and Designs Journal 2113

Proceedings under EC Regulations 1768/92 and 1610/96 (Supplementary Protection Certificates for Medicinal Products and Plant Protection Products, respectively)

These entries include details of all proceedings relating to Supplementary Protection Certificates. Applications for Supplementary Protection Certificates are numbered in a single yearly sequence commencing SPC/GB93/001 covering both medicinal and plant protection products and the same number is retained for the granted certificate. Proceedings are open to public inspection but the granted certificate is not separately published.

The entries are grouped in categories according to the type of proceedings. Within each category the entries are arranged in alphabetical order according to the name of the applicant for, or holder of, the certificate and provide the following information; the name and address of the applicant or holder; the product in respect of which the certificate has been applied for or granted; the product type; ie. "Medicinal" or "Plant Protection"; the number and date of the first authorisation under Directive 65/65/EEC or Directive 81/851/EEC to place the product on the market as a medicinal product in the United Kingdom or the number and date of the first authorisation under Article 4 of Directive 91/414/EEC or an equivalent provision of national law to place the product on the market as a plant protection product in the United Kingdom; where relevant, the country; number and date of the first authorisation to place the product on the market in the European Community; the number and title of the basic UK patent or European patent (UK) which protects the product; and the number of the application or certificate.

The entries will also state as appropriate: the filing date of the application; the date of grant or rejection of the application; the maximum period of the granted certificate; the effective period of the certificate on entry into force; and the date of lapse or invalidity of the certificate.

There follows three examples of entries under these proceedings. The first relates to a new application for a certificate based on a European patent designating the United Kingdom and having first authorisation of the product in the United Kingdom. The second example relates to a certificate granted based, once again, on a European patent designating the United Kingdom but with the first product authorisation in the EEC in Denmark. The third refers to a certificate entering into force based on a United Kingdom patent with first product authorisation in the EEC in Belgium.

SPCs EXPIRED

S.A. Nycomed Christiaens N.V.

Chaussee de Gand, 615, B-1080 Brussels, Belgium

Product: 3-Isopropylcarbamyisulphonamide-4-(3'-methyl)-phenylaminopyridine (Torsemide), optionally in the form of a physiologically compatible salt

Product Type: Medicinal

Authorised:

UK 0075/0073	26 April 1994
UK 0075/0074	26 April 1994
UK 0075/0075	26 April 1994
UK 0075/0076	26 April 1994
UK 0075/0077	26 April 1994
UK 0075/0079	26 April 1994

Example 1: Applications for Certificates Filed

(71) Ohmeda Pharmaceutical Products Division Inc.
110 Allen Road, Liberty Corner, NJ 07938 USA
(95) **Product:** 2-(Difluoromethoxy)-1,1,1,2-tetrafluoroethane ("Desflurane")
Product Type: Medicinal
(92) **Authorised:** UK 0022/0120 19 July 1993
(68) **Patent No:** EP(UK) 0285237 (54) 2-(Difluoromethoxy)-1,1,1,2-tetrafluoroethane as an anaesthetic
(21) SPC/GB93/175 (22) **Lodged:** 24 December 1993

Example 2: Certificates Granted

(73) Aktiebolaget Hassle
Karagatan 5,S-431 83 Molndal, Sweden
(95) **Product:** Felodipine
Product Type: Medicinal
(92) **Authorised:** UK 0017/0235-0236 15 November 1993
(93) DK 6499 21 January 1988
(68) **Patent No:** EP(UK) 0007293 (54) 2,6-dimethyl-4-(2,3-dichlorophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methyl ester-5-ethyl ester having hypotensive properties, process for its preparation and pharmaceutical preparations containing it.
(11) SPC/GB93/134 **Date Granted:** 14 January 1994
(94) **Maximum period expires:** 20 January 2003

Example 3: Certificates entered into force

(73) American Cyanamid Company
Burden Avenue, Township of Wayne, State of New Jersey 06904, United States of America
(95) **Product:** Felbinac (4-biphenyl acetic acid)
Product Type: Medicinal
(92) **Authorised:** UK 0095/0119 28 October 1988
(93) BE 536 1S 91 F 7 21 June 1988
(68) **Patent No:** GB 1402691(54) Compositions of 4-Biphenyl Acetic Acid
(11) SPC/GB93/151
(24) **Date entered into force:** 7 September 1993
(94) **Effective period expires:** 6 September 1998

BE 914S359F3 01 October 1985
BE 914S360F12 01 October 1985


Patent: GB 1477664, Pyridine derivatives

SPC/GB94/017 **Date Expired:** 13 April 2000



GB

COPY OF CERTIFICATE GRANTED
ON SPC/GB 93/039



EEC Regulation No. 1768/92

Supplementary Protection Certificate

In accordance with Article 10(1) of the above Regulation, Supplementary Protection Certificate No SPC/GB93/039 is hereby granted to Ciba-Geigy AG, in respect of the product

Cyromazine

protected by basic patent No GB 1587573 entitled "2-Cyclopropylamino-4,6-diamino-s-triazine derivatives and their use as insecticides".

This certificate will take effect (subject to the payment of the prescribed fees) at the end of the lawful term of the basic patent and its maximum period of duration in accordance with Article 13 will expire on 17 August 2002, subject to the provisions of Articles 14 and 15.

Dated this 1st day of July 1993

P.R.S. HARTNACK
Comptroller-General of Patents,
Designs and Trade Marks.

THE PATENT OFFICE
Newport, Gwent

[Appendix 12 follows]



APPENDIX 12

IE

**Gazette announcements showing (1) receipt of application for an SPC
and (2) grant of SPC****(1) Request for Grant of Supplementary Protection Certificate**

The name and address of the requester follow the number allocated to the request. The date in brackets following the name and address is the date of receipt of the request. The patent number is that under which the product in respect of which a certificate is sought is, allegedly, protected. Market authorisation references in respect of the product concerned are also shown.

SPC 2000003 PHARMACIA & UPJOHN S.P.A.,
Via Robert Koch, 1.2, 20152 Milano, Italy

(22 February 2000)

Patent No: 58949; SUBSTITUTED ANDROSTA-1,4-DIENE-3,17-DIONES AND
PROCESS FOR THEIR PREPARATION

Product: Exemestane

Market Authorisation: Ireland PA 16/63/1

12 November 1999

United Kingdom PL 00032/0236

16 December 1998

(2) Supplementary Protection Certificates Granted

The name and address of the grantee follow the number allocated to the application for grant of a certificate; this number applies also to the granted certificate. The date in brackets following the name and address is the date of grant of the certificate. The number of the basic patent and the title of the invention are followed by the name of the product for which the certificate is granted. Market authorisation references in respect of the product concerned are also shown, followed by the date of expiry of the certificate.

SPC 1999009 MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.,
18 rue Dicks, L 1417 Luxembourg

(09 August 1999)

Patent No: 48802, Mercapto derivatives of substituted prolines

Product: Zofenopril and its salts, in particular its calcium salt

Market Authorisation: Ireland, PA865/3/1-4 and PA865/4/1-4

04 March 1999

United Kingdom, PL 16239/0002-0005

30 July 1998

Certificate expires on: 09 August 2004

[Appendix 13 follows]




APPENDIX 13

IT

MINISTERIO DELL'INDUSTRIA
DEL COMERCIO E
DELL'ARTIGIANATO

DIREZIONE GENERALE DELLA
PRODUZIONE INDUSTRIALE

UFFICIO ITALIANO BREVETTI E MARCHI
- ROMA -



BOLLETINO UFFICIALE DEI
CERTIFICATI COMPLEMENTARI
DI PROTEZIONE PER I
MEDICINALI

**FEBBRAIO
1996**



Appendix 13, page 2

IT

**BOLLETTINO UFFICIALE
DEI CERTIFICATI COMPLEMENTARI DI PROTEZIONE
PER I MEDICINALI
(FEBBRAIO 1996)**

INDICE

Elenco delle domande di C.C.P. ex Reg. C.E.E. n. 1768/92 (n. UB96CCP522)	1
Elenco dei C.C.P. concessi ex Reg. C.E.E. N. 1768/92' (del 18/6/92 (nn. 420 - 421 - 520 - 522))	2
Revoche (nn. 422 - 423)	4
Annotazioni (n. 380)	5



IT

BUccp 02/96

DEPOSITI

p. 1

N. UB96CCP522 : DEP. 02/02/96

DENOMINAZIONE : 'RENORMAX' E 'SETRILAN' (SPIRAPRIL CLORIDRATO)

TITOLARE : SCHERING CORPORATION
di nazionalita' : STATUNITENSE
indirizzo : 2000 GALLOPING HILL KENILWORTH, NEW JERSEY 07033 (U.S.A.)RAPPRESENTANTE : RICCARDI SERGIO
dello Studio : UFFICIO BREVETTI RICCARDI & CO.
indirizzo : VIA MACEDONIO MELLONI, 32 20129 MILANO

BREVETTO N. 27424BE/95 DEL 18/06/86 DEP.15/10/81 (BREV. EUR. N. 0.050.800)

Autorizzazione all'immissione in commercio (Decreto del Ministero della Sanita')
rilasciata in data: 31/08/95 (nn. 547-546/1995)Titolo dell'invenzione:
"CARBOSSIALCHIL DIPEPTIDI, PROCEDIMENTI PER LA LORO PRODU-
ZIONE E COMPOSIZIONI FARMACEUTICHE CHE LI CONTENGONO".: ITALIA: LE AIC HANNO NN. 028582017 E 028583019.DEL 31/08/95.
: OLANDA: LA AIC HA N. RVG 15664 DEL 28/07/93.
: " : IL NOME COMMERCIALE E' 'RENPRESS'.



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.57

Appendix 13, page 4

IT

BUccp 02/96 CONCESSIONI EX REGOLAMENTO C.E.E. N.1768/92 p. 2

N. C-UB93CCP420: DEP. 01/03/93 CONC. IL 21/02/1996

DENOMINAZIONE : RECOMBIVAX HB (ANTIGENE DEL VIRUS DELL'EPATITE B), VACCINO
: CONTRO L'EPATITE B).

TITOLARE : BIOGEN, INC.
di nazionalita' : STATUNITENSE
indirizzo : CAMBRIDGE - MASSACHUSETTS - U.S.A.

RAPPRESENTANTE : RICCARDI S.
dello Studio : UFF. BREVETTI RICCARDI & CO.
indirizzo : V. M. MELLONI, 32 20129 MILANO

BREVETTO N. 20325BE\87 DEL 25/03/87 DEP 21/12/79 BREV. EUR. O.013.828

Autorizzazione all'immissione in commercio (Decreto del Ministero della Sanita')
rilasciata in data: 30/06/88

Titolo dell'invenzione:
"DNA RICOMBINANTE, OSPITE TRASFORMATO CON ESSO E POLIPEPTIDE
PRODOTTO DALL'OSPITE; METODO PER LA LORO PREPARAZIONE; METO-
DO DI RILEVAMENTO IMPIEGANTE IL POLIPEPTIDE"

Durata del CCP : 1 ANNO,4 MESI,25 GG. DAL 21/11/1999

: ITALIA: L'A.I.C. HA NN.026710018 E 026710020 (30/6/1988).
: GERMANIA:L'A.I.C. HA NN 582a/85, 583a/85, 45a/86 (16/5/1986)
: " IL PRODOTTO E' DENOMINATO "GEN-H-B VAX".

N. C-UB93CCP421: DEP. 01/03/93 CONC. IL 21/ 2/1996

DENOMINAZIONE : ENGERIX - B (ANTIGENE DEL VIRUS DELL'EPATITE B), VACCINO
: MONODOSE ANTIEPATITE).

TITOLARE : BIOGEN, INC.
di nazionalita' : STATUNITENSE
indirizzo : CAMBRIDGE - MASSACHUSETTS - U.S.A.

RAPPRESENTANTE : RICCARDI S.
dello Studio : UFF. BREVETTI RICCARDI & CO.
indirizzo : V. M. MELLONI,32 20129 MILANO

BREVETTO N. 22629BE\90 DEL 11/07/90 DEP. 21.12.79 BREV. EUR. O.182.442

Autorizzazione all'immissione in commercio (Decreto del Ministero della Sanita')
rilasciata in data: 18/09/87

Titolo dell'invenzione:
"MOLECOLE DI DNA RICOMBINANTE E METODO PER LA LORO PREPARA-
ZIONE"

Durata del CCP : 1 ANNO,10 MESI,24 GG. DAL 21/12/99

: ITALIA: L'A.I.C. HA NN. 026653016/28/30/42 (18/9/1987).
: BELGIO: L'A.I.C. HA N. 18 S 354 F 17 (14/11/1986).

N. C-UB96CCP520: DEP. 10/01/96 CONC. IL 22/02/1996

DENOMINAZIONE : "ENABLEX" E "REUMATEN" (TENIDAP SODICO)
:

TITOLARE : PFIZER INC.
di nazionalita' : STATUNITENSE
indirizzo : NEW-YORK - U.S.A.

RAPPRESENTANTE : ING. G. MODIANO
dello Studio : MODIANO & ASSOCIATI
indirizzo : VIA MERAVIGLI, 16 20129 MILANO

BREVETTO N. 24676BE/89 DEL 23/08/89 DEP. 15/03/85 (BREV. EUR. O.156.603)

Autorizzazione all'immissione in commercio (Decreto del Ministero della Sanita')
rilasciata in data: 11/08/95 (n. 536/1995)

Titolo dell'invenzione:
"2-OSSINDOLO-1-CARBOSSAMIDI: 3-SOSTITUIUTE COME AGENTI
ANALGESICI ED ANTI-Infiammatori"

Durata del CCP : 4 ANNI, 6 MESI, 4 GG. DAL 15/3/2005

: ITALIA: LE A.I.C. HANNO NN. 029228018-20-32-44, 29208016-28-
: 30-42 DELL'11/08/95.
: OLANDA: LE A.I.C. HANNO NN. 16999 E 17000 DEL 19/09/94.



IT

BUccp.02/96 REVOCHE P. 4

UB93CCP422

- In data 16/2/1996 si e' provveduto a revocare il CCP sopra indicato (su richiesta del Titolare) concesso nel mese di Dicembre 1995.
- BREVETTO N. 20325/BE/87 CONC. 25/03/87 DEP. 21/12/79 (brev. eur. n. 0.013.828)
- denominazione "ENGERIX B" (ANTIGENE DEL VIRUS DELL' EPATITE B), VACCINO MONODOSE ANTIEPATITE)
- Titolare: BIOGEN INC.

UB93CCP423

- In data 16/2/1996 si e' provveduto a revocare il CCP sopra indicato (su richiesta del Titolare) concesso nel mese di Dicembre 1996.
- BREVETTO N. 22629/BE/90 CONC. 11/07/90 DEP. 21/12/79 (brev. eur. n. 0.182.422)
- denominazione "RECOMBIVAX HB (ANTIGENE DEL VIRUS DELL' EPATITE B), VACCINO CONTRO L' EPATITE B)
- Titolare: BIOGEN INC.



IT

BUccp 02/96

ANNOTAZIONI

P. 5

UB92CCP380

- Il Ministero della Sanità ha modificato la denominazione della specialità medicinale HYPOGON in "GLUCAGEN";
- Il CCP sopra indicato, concesso il 5/06/1995, viene corretto con la nuova denominazione;
- BREVETTO N. 20337/BE/90 CONC. IL 13/12/89 DEP. il 20/01/86 (brev. eur. n. 0189998)
- denominazione: "GLUCAGEN"
- Titolare: NOVO NORDISK A/S

[Appendix 14 follows]



APPENDIX 14

JP

出願番号	特許番号	延長を求めた期間	特許法第77条第3項の政令で定める趣旨の内容	出願人	住所
3-700001	1102636	2年9月12日	<p>特許法の存続期間の延長登録の理由となる趣旨</p> <p>(1) 特許法の存続期間の延長登録の理由となる趣旨 <i>law under which authorization is obtained</i> 農薬取締法第2条第1項に規定する農薬登録</p> <p>(2) 趣旨を特定する通号、Number of authorization 農薬登録第17722号</p> <p>(3) 趣旨の対象となつた有効成分化合物 一般的名称：ニルベマクソン <i>is authorized product to</i></p> <p>(4) 趣旨の対象となつた用途、uses of the product 茶（夏下栽培を除く） のカンザクハダニの防除</p>	三共株式会社（外1名） 5番1号	東京都中央区日本橋本町3丁目 5番1号
3-700002	1112991	2年9月12日	<p>特許法の存続期間の延長登録の理由となる趣旨</p> <p>(1) 特許法の存続期間の延長登録の理由となる趣旨 農薬取締法第2条第1項に規定する通号</p> <p>(2) 趣旨を特定する通号 農薬登録第17722号</p> <p>(3) 趣旨の対象となつた有効成分化合物 一般的名称：ニルベマクソン</p> <p>(4) 趣旨の対象となつた用途 茶（夏下栽培を除く） のカンザクハダニの防除</p>	三共株式会社（外1名） 5番1号	東京都中央区日本橋本町3丁目 5番1号

number allotted to receipt of the application Patent number to be granted

Terms requested to be granted

Publication of applications for SPCs

特許法の存続期間の延長登録の理由

Name Applicant Address



APPENDIX 15

LU



MINISTERE DE L'ECONOMIE
SERVICE DE LA PROPRIETE INTELLECTUELLE

**CERTIFICAT COMPLEMENTAIRE DE
PROTECTION POUR MEDICAMENT**

Règlement CEE No 1768/92 du Conseil du 18.06.1992
concernant la création d'un certificat complémentaire de protection pour
les médicaments

Date de délivrance du certificat complémentaire: X

Numéro du certificat complémentaire: X

Titre du certificat complémentaire:

Titulaire: X
X
X

Date de dépôt et Numéro du brevet de base: X

Titre du brevet de base:

Date de la première autorisation de mise sur le marché dans la CEE X

Ce certificat prendra effet à l'expiration du brevet de base.

Vu l'article 13 du règlement CEE No 1768/92 le certificat complémentaire de protection
viendra à terme le 00.00.0000

Mandataire:

Luxembourg, le

Pour le Ministre de l'Économie

Serge Allegrezza
Attaché de Gouvernement

[Appendix 16 follows]



APPENDIX 16

LV

Patenta spēkā esamības termiņu pagarināšana

PATENTI UN PREČU ZĪMES - 20.10.1999

Pieteikumi patenta spēkā esamības termiņu pagarināšanai

(LR Patentu likuma 7(9), 31(5) pants)

- | |
|--|
| (92) Ārstniecības līdzekļa reģistrācijas apliecības numurs un izsniegšanas datums. |
| (94) Datums, līdz kuram pagarināts patenta darbības termiņš. |
| (95) Produkta nosaukums patentā. |
| (96) Patentpieteikuma numurs, iesniegšanas datums. |
| (97) Patenta numurs, patenta publikācijas datums. |

- | | |
|---|-----------------|
| (21) C-99-02 | (22) 13.09.1999 |
| (54) Jauni sulfonamidu fibrinogēna receptora antagonisti | |
| (73) MERC&CO., 126, East Lincoln Avenue, P.O.Box 2000, Rahway | |
| (74) Ābrams FOGELS, Patentu birojs "ALFA-PATENTS", Virānes iela 2, Rīga LV-1073, LV | |
| (92) 99-0206, | 17.03.1999; |
| (95) 2-S-benzil-sulfonilamino-3-[4-(piperidīn-4-il)butiloksi-fenil]propionskābe un tās etilēsteris (AGGRASTAT); | |
| (96) P-95-267, | 27.09.1990 |
| (97) 5746, | 20.08.1997; |

This is an announcement concerning application for SPC.

Pagarinātie patenta spēkā esamības termiņi

- | | |
|---|-----------------|
| (21) C-99-01 | (22) 02.06.1999 |
| (54) Benzimidazola atvasinājumi, to iegūšana un izmantošana farmaceutiskās kompozīcijās | |
| (73) TAKEDA CHEMICAL INDUSTRIES Ltd., 1-1, Doshomachi 4-chome. Chuo-ku, Osaka 541-0045 Japan; | |
| (74) Vladimirs ANOHINS, Aģentūra "TRIA ROBIT", Aizkraukles iela 23, Rīga LV-1006, LV | |
| (92) 99-0117, | 17.02.1999; |
| (94) 17.02.2014 | |
| (95) 1-(Cikloheksiloksikarboniloksi)-etil-2-etoksi-1-[[2'-(1H-tetrazol-5-il)ifenil-4-il]metil]benzimidazol-7-karboksilāta stabils kristāls (ATACAND); | |
| (96) P-92-567, | 30.12.1992 |
| (97) 10258, | 20.04.1995; |

This is an announcement concerning extended patent term.

The difference is in a date marked by (94).

[Appendix 17 follows]



APPENDIX 17

NL

3 juli 2000, nr. 7

De Industriële Eigendom

999

Rubriek AC. Aanvragen voor een aanvullend beschermingscertificaat voor geneesmiddelen.**(Rubriek AC) Onderdeel 1. Opsomming in nummervolgorde.**

① 300006	⑤ Imidazolylelkeenzuurderivaten.	⑤ Eprosartan.
② 16.05.2000	⑦ Mr. Ir. A.W. Prins c.s. te 2508 DH Den Haag.	③ 39573.00.00 27.08.1997
① Smithkline Beecham Corporation te Philadelphia, Pennsylvania, Verenigde Staten van Amerika (US).	③ RVG 22258 06.01.1998	③ 39573.01.00 27.08.1997
③ EP 0403159	③ RVG 22259 06.01.1998	③ 39573.02.00 27.08.1997
	③ RVG 22260 06.01.1998	

(Rubriek AC) Onderdeel 2. Opsomming van de in onderdeel 1 genoemde aanvragen voor een beschermingscertificaat in alfabetische volgorde van de namen van de aanvragers.

① Smithkline Beecham Corporation te Philadelphia, Pennsylvania, Verenigde Staten van Amerika (US).	① 300006
	② 16.05.2000



NL

1000

De Industriële Eigendom

3 juli 2000, nr. 7

Rubriek KC. Verlening van aanvullende beschermingscertificaten voor geneesmiddelen.**(Rubriek KC) Onderdeel 1. Opsomming in nummervolgorde.**

<p>① 990017</p> <p>② Pharmacia & Upjohn Aktiebolag te Stockholm, Zweden (SE).</p> <p>④ Dr. R. Jorritsma c.s. te 2517 KZ Den Haag.</p> <p>⑤ 16.01.2004 15.01.2009</p> <p>⑥ EP 0121036</p> <p>⑦ Produkt voor geregelde triglyceridevoeding van hyperkatabole zoogdieren.</p> <p>⑧ RVG 23535 08.02.1999</p> <p>⑨ Triglycerida Structurate Purificata.</p> <p>⑩ 13002 11.10.1996</p> <p>(Zie volgende kolom)</p>	<p>③ 02.08.1999/08</p> <hr/> <p>⑪ 990038</p> <p>⑫ THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce te Springfield, Virginia 22161, Verenigde Staten van Amerika (US).</p> <p>⑬ Mr. G.L. Kooy c.s. te 2514 BB Den Haag.</p> <p>⑭ 26.06.2004 25.06.2009</p> <p>⑮ EP 0130906</p> <p>⑯ Genetische herrangschikking van</p>	<p>rotavirussen voor de produktie van vaccins en vaccinvoorlopers.</p> <p>⑰ EU/1/99/105/001 07.05.1999</p> <p>⑱ Combinatie van rhesus rotavirus serotype 3, reassortant rhesus/humaan rotavirus serotype 1, reassortant rhesus/humaan rotavirus serotype 2 en reassortant rhesus/humaan rotavirus serotype 4.</p> <p>⑲ EU/1/99/105/001 07.05.1999</p> <p>⑳ 03.01.2000/01</p>
--	---	--

(Rubriek KC) Onderdeel 2. Opsomming van de in onderdeel 1 genoemde verleende beschermingscertificaten in alfabetische volgorde van de namen van de certificaathouders.

<p>⑰ Pharmacia & Upjohn Aktiebolag te Stockholm, Zweden (SE).</p> <p>⑪ 990017</p>	<p>⑫ THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce te</p>	<p>Springfield, Virginia 22161, Verenigde Staten van Amerika (US).</p> <p>⑪ 990038</p>
---	---	--

[Appendix 18 follows]



APPENDIX 18

NO

NORSK PATENTTIDENDE

19/00

Meddelt supplerende beskyttelsessertifikater

Kunngjøring etter PF § 85

Soknad nr. Inngivelsesday	Basis patent nr.	Soker Fullmæktig	Produkt Gyldig i o m NO markedsføringstillatelse nr. Dato for samme Første markedsføringstillatelse innen EOS-området Dato for samme	Oppfinnelsens benevnelse
SPC/NO 1998002 14.01.1998	170284	Bristol-Myers Squibb Co P O Bøx 5100 Wallingford, CT 06492-7660, US Dag Dawes - Bryn & Aarflot AS 0104 Oslo	Etoposide-fosfat 12.04.2011 951139 23.10.1997 SE 12512 12.04.1996	Analogifremgangsmåte til fremstilling av farmakologisk aktive 4'-fo sfatderivater av 4'-demety letpodofylloretoksinglukosider
SPC/NO 1999005 09.04.1999	180447	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon, Hertfordshire EN11 9BU, England, GB Tandbergs Patentkontor AS 0306 Oslo	Rizatriptan 11.02.2013 97-2719 19.02.1999 NL 21815.-16 11.02.1998	imidazol-, triazol- og tetrazolderivater, farmasøytiske preparater inneholdende disse, og anvendelse av forbindelsene for fremstilling av medikamenter
SPC/NO 1999024 30.11.1999	301585	Dr. Karl Thomae GmbH D-88397 Biberach, DE Johan H Gorbitz - Bryn & Aarflot AS 0104 Oslo	Telmisartan 11.12.2013 98-5024 12.10.1999 EP EU-1/98-08 11.12.1998	Benzimidazol- og legemidler inneholdende disse

Tilbaketatte, avslåtte eller henlagte patentsøknader som er allment tilgjengelige

19931523 19931995 19933209 19934402 19941973 19942313 19942920 19943399 19943534 19943726
 19952234 19952243 19952848 19953921 19960215 19963248 19964263 19964812 19964870 19971382
 19971761 19974909 19975951



Appendix 18, page 2

NO

NORSK PATENTTIDENDE					19/00
Innsigelse mot patent					Kunngjøring etter PL § 24, 5 ledd og PB § 20-6
(51) IPC klasse	(11) Patent nr (21) Patent søknad nr	(73) Patenthaver	Innsiger	Kunngjøring av meddelt patent	
			Dato for innsigelsen		
			Fullmektig for innsigeren		
A 61 K 49:00	305685 19923424	(73) Hoechst AG. D-65926 Frankfurt am Main, DE	Nycomed Imaging AS Oslo, NO 12.04.2000	Løke 28 99	
Ingen					
C 12 N 1/16 C 12 P 23:00 A 23 K 1/18	305762 19885560	(73) Gist-Brocades NV. Postbus 1, NL-2600 MA Delft, NL	Kyowa Hakko Kogyo Co Ltd Tokyo, JP K-I Chemical Industry Co Ltd Shizuoka-ken, JP Idun Industri AS Oslo, NO 18.04.2000	Uke 29 99	
Bryns Patentkontor AS,Oslo					
C 12 N 1/16 C 12 P 23:00 A 23 K 1/18	305762 19885560	(73) Gist-Brocades NV. Postbus 1, NL-2600 MA Delft, NL	Archer-Daniels-Midland Co Decatur, IL, US 19.04.2000	Uke 29 99	
Bryns Patentkontor AS,Oslo					
Nye søknader om supplerende beskyttelsessertifikater					Kunngjøring etter PF § 80
Søknad nr Inngivelsesdag	Basis patent nr	Søker	Produkt NO markedsføringstillatelse nr. Dato for samme Første markedsføringstillatelse innen EOS-området Dato for samme	Oppfinnelsens benevnelse	
SPC/NO 2000001 13.04.00	177702	Merck & Co Inc 126 East Lincoln Avenue Rahway, NJ 07065, US Tandbergs Patentkontor AS 0306 Oslo	Tirofiban, eventuelt i form av et farmasøytisk akseptabelt salt, fortrinnsvis hydroklorid 97-5096 08.12.99 CH 54761 28.04.98	Analogifremgangsmåte for fremstilling av terapeutisk aktive forbindelser	

[Appendix 19 follows]



APPENDIX 19

PT

5014

BOLETIM DA PROPRIEDADE INDUSTRIAL N.º 12 — 1999

Certificados complementares de protecção

Menções de concessão

Pedidos

A publicação dos pedidos de certificados complementares de protecção a seguir indicados é feita nos termos dos Regulamentos (CE) do Conselho n.º 1768/92, de 18 de Julho, e 1610/96, de 23 de Julho.

Processo	Tipo de dado	Conteúdo dos dados	País resd.
48 T	(68) — Patente de base Data da concessão (94) — Duração/vigência (73) — 1.º titular..... (54) — Epígrafe do invento (95) — Prod. (medicamento) (93) — 1.º aut. com. na U. E. ... (92) — Aut. com. nacional.....	N.º 99776 M, de 1991.12.12. 1999.12.15 (22) — Data do pedido: 1999.07.21. Início em 2014.02.25 e fim em 2014.04.28. Nome: Bayer Aktiengesellschaft. Morada: 5090 Leverkusen, Bayerwerk. Processo para a preparação de ácido piridil-di-hidroxi-heptenóico substituído e de seus sais. Cervastatina (Lipobay). Data: 1997.02.13 — País: GB — Número: PL00010/0226. Data: 1998.05.15 — País: PT — Número: UK/H/184/01-03.	DE
53 P	(68) — Patente de base Data da concessão (94) — Duração/vigência (73) — 1.º titular..... (54) — Epígrafe do invento (95) — Prod. (medicamento) (93) — 1.º aut. com. na U. E. (92) — Aut. com. nacional.....	N.º 97460 Z, de 1991.04.24. 1999.12.13 (22) — Data do pedido: 1999.09.10. Início em 2013.10.10 e fim em 2016.07.25. Nome: Biota Scientific Management Pty, Ltd. Morada: Level 4, 616 ST Kilda Road, Melbourne, Victoria 3004. Processo para a preparação de compostos anti-vírus derivados de ácido α -neuramínico e das suas formulações farmacêuticas. Zanamivir (Relenza). Data: 1999.02.09 — País: SE — Número: 14 997. Data: 1999.06.17 — País: PT — Número: SE/H/180.	AU
55 S	(68) — Patente de base Data da concessão (94) — Duração/vigência (73) — 1.º titular..... (54) — Epígrafe do invento (95) — Prod. (medicamento) (93) — 1.º aut. com. na U. E. (92) — Aut. com. nacional.....	N.º 96321 C, de 1990.12.21. 1999.12.06 (22) — Data do pedido: 1999.09.24. Início em 2013.04.02 e fim em 2016.10.10. Nome: Wellcome Foundation Limited, The. Morada: Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN. Processo para a preparação de nucleósidos de purina. Sulfato de abacavir (Ziagen). Data: 1999.06.28 — País: CH — Número: 55048. Data: 1999.07.08 — País: PT — Número: C(1999)1908.	GB
56 T	(68) — Patente de base Data da concessão (94) — Duração/vigência (73) — 1.º titular..... (54) — Epígrafe do invento (95) — Prod. (medicamento) (93) — 1.º aut. com. na U. E. ... (92) — Aut. com. nacional.....	N.º 88261 G, de 1988.08.12. 1999.12.06 (22) — Data do pedido: 1999.10.06. Início em 2009.08.05 e fim em 2010.12.13. Nome: Wellcome Foundation Limited, The. Morada: Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN. Processo para a preparação de nucleósidos com efeito terapêutico. Valaciclovir (Valtrex). Data: 1994.12.20 — País: IE — Número: PA17/111/1. Data: 1999.08.04 — País: PT — Número: 185/94.	GB
57 U	(68) — Patente de base Data da concessão (94) — Duração/vigência (73) — 1.º titular..... (54) — Epígrafe do invento (95) — Prod. (medicamento) (92) — Aut. com. nacional.....	N.º 80758 P, de 1985.07.03. 1999.12.15 (22) — Data do pedido: 1999.10.12. Início em 2006.02.17 e fim em 2011.02.17. Nome: Genentech, Inc. Morada: 1 DNA Way, S. San Francisco, CA 94 080-4990. Método para a preparação de factor de necrose tumoral. Tasonormia (Beromun). Data: 1999.04.13 — País: PT — Número: C(1999)933.	US
59 X	(68) — Patente de base Data da concessão (94) — Duração/vigência (73) — 1.º titular..... (54) — Epígrafe do invento (95) — Prod. (medicamento) (92) — Aut. com. nacional.....	N.º 70396 V, de 1979.12.14. 1999.12.15 (22) — Data do pedido: 1999.12.03. Início em 2000.02.07 e fim em 2005.02.07. Nome: Hoechst Aktiengesellschaft. Morada: D-6230 Frankfurt/Main 80. Processo para a preparação de um derivado de isoxazol e de composições farmacêuticas que contêm este composto. Leflunomida (Arava). Data: 1999.09.02 — País: PT — Número: C(1999)2850.	DE

[Appendix 20 follows]



APPENDIX 20

SE

PRV

PATENT- OCH REGISTRERINGSVERKET

The Swedish certificate

EG-FÖRORDNINGEN 1768/92

BEVIS OM TILLÄGGSSKYDD 9990029-2

Meddelat 1999-12-20

I enlighet med artikel 10.1 i ovanstående förordning meddelas tilläggsskydd på produkten Becaplermin (rekombinant human blodplättshärledd tillväxtfaktor-BB, rh PDGF-BB).

Produkten skyddas av grundpatentet EP 85112852.0 (0177957)

Innehavare av tilläggsskyddet

ZymoGenetics, Inc

Tilläggsskyddet inträder from 2005-10-11

och kan upprätthållas t o m 2010-10-10

För varje påbörjat avgiftsår skall en årsavgift betalas för tilläggsskyddet.

Första årsavgiften förfaller till betalning 2005-10-31

I tjänsten

Gerd Strandell



SE

Ansökan om tilläggskydd för läkemedel

A61K 31/165	---	>	(51)	C07C 311/02
A61K 31/395	---	>	(51)	C07C 311/02
C07C 211/45	---	>	(51)	C07C 311/02
C07C 215/42	---	>	(51)	C07C 311/02
C07C 217/64	---	>	(51)	C07C 311/02
C07C 233/64	---	>	(51)	C07C 311/02
C07C 237/28	---	>	(51)	C07C 311/02
(51) C07C 311/02			(21)	0090007-6 L
C07C 311/15				C07C 317/14
C07D 295/18				C07C 233/64
C07C 237/28				C07C 215/42
C07C 217/64				C07C 211/45
A61K 31/165				A61K 31/395
(21) 87303782.4			(11)	0 245 997
(92) 1999-11-29	EG			EU/1/99/121/001
(93) 1999-11-29	EG			EU/1/99/121/001
(95) Dofetilide, eventuellt i form av ett farmaceutiskt föredraget salt				
(54) N-substituerade P-aminoetylsulfonamilider som antiarytmika samt mellanprodukter för dessa				
(71) Pfizer Limited, Sandwich Kent CT13 9NJ,				
C07C 311/15	---	>	(51)	C07C 311/02
C07C 317/14	---	>	(51)	C07C 311/02
C07D 295/18	---	>	(51)	C07C 311/02

[Appendix 21 follows]



APPENDIX 21

US

4432

Federal Register / Vol. 65, No. 18 / Thursday, January 27, 2000 / Notices

and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Claudia V. Grillo, Regulatory Policy Staff (HFD-007), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-5645.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Commissioner of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA recently approved for marketing the human drug product Ziagen™ (abacavir). Ziagen™ is indicated for the treatment of HIV-1 infection. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for Ziagen™ (U.S. Patent No. 5,034,394) from Glaxo Wellcome, Inc., and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated May 10, 1999, FDA advised the Patent and Trademark Office that this human drug product had undergone a regulatory review period and that the approval of Ziagen™ represented the first permitted commercial marketing or use of the

product. Shortly thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period.

FDA has determined that the applicable regulatory review period for Ziagen™ is 1,632 days. Of this time, 1,455 days occurred during the testing phase of the regulatory review period, while 177 days occurred during the approval phase. These periods of time were derived from the following dates:

1. *The date an exemption under section 505 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355) became effective:* July 1, 1994. The applicant claims June 28, 1994, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was July 1, 1994, which was 30 days after FDA receipt of the IND.

2. *The date the application was initially submitted with respect to the human drug product under section 505 of the act:* June 24, 1998. FDA has verified the applicant's claim that the new drug application (NDA) for Ziagen™ (NDA 20-977) was initially submitted on June 24, 1998.

3. *The date the application was approved:* December 17, 1998. FDA has verified the applicant's claim that NDA 20-977 was approved on December 17, 1998.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 906 days of patent term extension.

Anyone with knowledge that any of the dates as published is incorrect may, on or before March 25, 2000, submit to the Dockets Management Branch (address above) written comments and ask for a redetermination. Furthermore, any interested person may petition FDA, on or before July 25, 2000, for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Comments and petitions should be submitted to the Dockets Management Branch (address above) in three copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the

heading of this document. Comments and petitions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: December 23, 1999.

Jane A. Axelrad,
Associate Director for Policy, Center for Drug Evaluation and Research.

[FR Doc. 00-1871 Filed 1-26-00; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98E-0853]

Determination of Regulatory Review Period for Purposes of Patent Extension; GlucaGen®

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for GlucaGen® and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

ADDRESSES: Submit written comments and petitions to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Claudia V. Grillo, Regulatory Policy Staff (HFD-007), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-5645.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug



US

products, the testing phase begins when the exemption to permit the clinical investigations of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Commissioner of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA recently approved for marketing the human drug product GlucaGen® (glucagon (rDNA origin)). GlucaGen® is indicated for the treatment of hypoglycemia. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for GlucaGen® (U.S. Patent No. 4,826,763) from Novo Nordisk A/S, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated May 27, 1999, FDA advised the Patent and Trademark Office that this human drug product had undergone a regulatory review period and that the approval of GlucaGen® represented the first permitted commercial marketing or use of the product. Shortly thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period.

FDA has determined that the applicable regulatory review period for GlucaGen® is 2,569 days. Of this time, 2,296 days occurred during the testing phase of the regulatory review period, while 273 days occurred during the approval phase. These periods of time were derived from the following dates:

1. *The date an exemption under section 505 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355) became effective:* June 12, 1991. The applicant claims June 13, 1991, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was June 12, 1991, which was 30 days after FDA receipt of the IND.

2. *The date the application was initially submitted with respect to the human drug product under section 505 of the act:* September 23, 1997. The applicant claims September 18, 1997, as

the date the new drug application (NDA) for GlucaGen® (NDA 20-918) was initially submitted. However, FDA records indicate that NDA 20-918 was submitted on September 23, 1997.

3. *The date the application was approved:* June 22, 1998. FDA has verified the applicant's claim that NDA 20-918 was approved on June 22, 1998.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 1,423 days of patent term extension.

Anyone with knowledge that any of the dates as published is incorrect may, on or before March 21, 2000, submit to the Dockets Management Branch (address above) written comments and ask for a redetermination. Furthermore, any interested person may petition FDA, on or before July 25, 2000, for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Comments and petitions should be submitted to the Dockets Management Branch (address above) in three copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: December 23, 1999.

Jane A. Axelrad,
Associate Director for Policy, Center for Drug Evaluation and Research.

[FR Doc. 00-1872 Filed 1-26-00; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99E-0119]

Determination of Regulatory Review Period for Purposes of Patent Extension; Sentinel Model 2000/2010®

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for Sentinel Model 2000/2010® and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.

ADDRESSES: Submit written comments and petitions to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Claudia V. Grillo, Regulatory Policy Staff (HFD-007), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-5645.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100-670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For medical devices, the testing phase begins with a clinical investigation of the device and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the device and continues until permission to market the device is granted. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Commissioner of Patents and Trademarks may award (half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a medical device will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(3)(B).

FDA recently approved for marketing the medical device Sentinel Model 2000/2010®. Sentinel Model 2000/2010® is indicated for use in patients with documented ventricular fibrillation and/or ventricular tachycardia, or in



US

Patent Terms Extended Under 35 U.S.C. §156

Certificates extending the terms of the following patents were issued on April 24, 1992.

U.S. Patent No. Re. 30,577; Reissued April 14, 1981, to Norbert Busch et al.; Owner of Record: *Rim Laboratories C.E.R.M.*; Title: ETHER OF N-PROPANOL AMINE; Classification: 548/569; Product Trade Name: Bepadin/Vascor; Term Extended: Two years.

U.S. Patent No. Re. 32,969; Reissued June 27, 1989 to Seymour F. Trager, et. al.; Owner of Record: *Inventors*; Title: INJECTIONABLE VISCOELASTIC OPHTHALMIC GEL; Classification: 424/81; Product Trade Name: Otcolon; Term Extended: 931 days

U.S. Patent No. 4,337,201; Granted June 29, 1982, to Edward W. Petrillo, Jr.; Owner of Record: *E. R. Squibb & Sons, Inc.*; Title: PHOSPHINYALKANOYL SUBSTITUTED PROLINES; Classification: 548/413; Product Trade Name: Monopril; Term Extended: Two years.

U.S. Patent No. 4,410,520; Granted: Oct. 18, 1983, to Jeffrey W. H. Wathey; Owner of Record: *Ciba-Geigy Corp.*; Title: 3-AMINO-(1)-BENZAZEPIN-2-ONE-1-ALKANOIC ACIDS; Classification: 514/212; Product Trade Name: Lotensin; Term Extended: Two years.

U.S. Patent No. 4,701,460; Granted: Oct. 20, 1987, to Hassan A. El-Sayad et al.; Owner of Record: *Burroughs Wellcome Co.*; Title: LONG DURATION NEUROMUSCULAR BLOCKING AGENTS; Classification: 514/308; Product Trade Name: Nuromax; Term Extended: 137 days.



US

UNITED STATES PATENT AND TRADEMARK OFFICE

**CERTIFICATE EXTENDING PATENT TERM
UNDER 35 U.S.C. § 156**

PATENT NO.: 3,998,790
DATED: December 21, 1976
INVENTORS: Arne Elof Brandstrom et al.
PATENT OWNER: Aktiebolaget Hassle

This is to certify that there has been presented to the

COMMISSIONER OF PATENTS AND TRADEMARKS

an application under 35 U.S.C. § 156 for an extension of the patent term. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

2 YEARS

with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the Patent and Trademark Office to be affixed this 20th day of May 1993.

Michael K. Kirk
Acting Commissioner of Patents and Trademarks

[End of Appendix 21 and of Survey]



HANDBOOK ON INDUSTRIAL PROPERTY INFORMATION AND DOCUMENTATION

Ref.: Examples and IPO practices

page: 7.7.75
